US20140335066A1 - Lactobacillus plantarum inducia dsm 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against clostridium difficile - Google Patents
Lactobacillus plantarum inducia dsm 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against clostridium difficile Download PDFInfo
- Publication number
- US20140335066A1 US20140335066A1 US14/244,284 US201414244284A US2014335066A1 US 20140335066 A1 US20140335066 A1 US 20140335066A1 US 201414244284 A US201414244284 A US 201414244284A US 2014335066 A1 US2014335066 A1 US 2014335066A1
- Authority
- US
- United States
- Prior art keywords
- food product
- composition
- plantarum inducia
- difficile
- dsm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 185
- 241000193163 Clostridioides difficile Species 0.000 title claims abstract description 120
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 68
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 68
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 22
- 230000007969 cellular immunity Effects 0.000 title claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 8
- 239000004599 antimicrobial Substances 0.000 title claims abstract description 5
- 239000003623 enhancer Substances 0.000 title claims abstract description 4
- 230000000871 hypocholesterolemic effect Effects 0.000 title abstract 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 71
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 70
- 239000000811 xylitol Substances 0.000 claims abstract description 70
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 70
- 235000010447 xylitol Nutrition 0.000 claims abstract description 70
- 229960002675 xylitol Drugs 0.000 claims abstract description 70
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 33
- 210000004369 blood Anatomy 0.000 claims abstract description 31
- 239000008280 blood Substances 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 108010028554 LDL Cholesterol Proteins 0.000 claims abstract description 22
- 238000008214 LDL Cholesterol Methods 0.000 claims abstract description 17
- 108010071584 oxidized low density lipoprotein Proteins 0.000 claims abstract description 13
- 230000037125 natural defense Effects 0.000 claims abstract description 8
- 230000035784 germination Effects 0.000 claims abstract description 7
- 244000005700 microbiome Species 0.000 claims abstract description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 6
- 230000035755 proliferation Effects 0.000 claims abstract description 5
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 4
- 235000013351 cheese Nutrition 0.000 claims description 68
- 239000006041 probiotic Substances 0.000 claims description 60
- 235000018291 probiotics Nutrition 0.000 claims description 60
- 230000000529 probiotic effect Effects 0.000 claims description 44
- 235000013305 food Nutrition 0.000 claims description 38
- 235000013618 yogurt Nutrition 0.000 claims description 33
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 235000015872 dietary supplement Nutrition 0.000 claims description 8
- 235000013365 dairy product Nutrition 0.000 claims description 6
- 239000003529 anticholesteremic agent Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 235000014048 cultured milk product Nutrition 0.000 claims 2
- 230000000845 anti-microbial effect Effects 0.000 abstract description 17
- 230000007423 decrease Effects 0.000 abstract description 5
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 58
- 230000012010 growth Effects 0.000 description 33
- 241000186660 Lactobacillus Species 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 32
- 229920000768 polyamine Polymers 0.000 description 32
- 239000005700 Putrescine Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 23
- 238000000034 method Methods 0.000 description 23
- 241000699800 Cricetinae Species 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 description 17
- 210000002700 urine Anatomy 0.000 description 17
- 150000001412 amines Chemical class 0.000 description 16
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 16
- 229960000723 ampicillin Drugs 0.000 description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 102000004889 Interleukin-6 Human genes 0.000 description 15
- 108090001005 Interleukin-6 Proteins 0.000 description 15
- 230000000035 biogenic effect Effects 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 239000003053 toxin Substances 0.000 description 15
- 231100000765 toxin Toxicity 0.000 description 15
- 108700012359 toxins Proteins 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 14
- 108010000231 Choloylglycine hydrolase Proteins 0.000 description 13
- 210000003405 ileum Anatomy 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 244000005709 gut microbiome Species 0.000 description 10
- 235000013336 milk Nutrition 0.000 description 10
- 239000008267 milk Substances 0.000 description 10
- 210000004080 milk Anatomy 0.000 description 10
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 10
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 9
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 229960003104 ornithine Drugs 0.000 description 9
- 239000004475 Arginine Substances 0.000 description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 230000000770 proinflammatory effect Effects 0.000 description 8
- 229960003732 tyramine Drugs 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 206010020565 Hyperaemia Diseases 0.000 description 7
- 241000736262 Microbiota Species 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 210000004347 intestinal mucosa Anatomy 0.000 description 7
- 229940039696 lactobacillus Drugs 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 208000037384 Clostridium Infections Diseases 0.000 description 5
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 5
- 206010054236 Clostridium difficile infection Diseases 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000003042 antagnostic effect Effects 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000006114 decarboxylation reaction Methods 0.000 description 5
- 230000007123 defense Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000001630 jejunum Anatomy 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 229940063673 spermidine Drugs 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 description 4
- 241000186605 Lactobacillus paracasei Species 0.000 description 4
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 4
- KLZGKIDSEJWEDW-UHFFFAOYSA-N N-acetylputrescine Chemical compound CC(=O)NCCCCN KLZGKIDSEJWEDW-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000007621 bhi medium Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 238000011553 hamster model Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 244000005706 microflora Species 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 241000186840 Lactobacillus fermentum Species 0.000 description 3
- 240000002129 Malva sylvestris Species 0.000 description 3
- 235000006770 Malva sylvestris Nutrition 0.000 description 3
- 241000699673 Mesocricetus auratus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FONIWJIDLJEJTL-UHFFFAOYSA-N N(8)-acetylspermidine Chemical compound CC(=O)NCCCCNCCCN FONIWJIDLJEJTL-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000028235 central diabetes insipidus Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000007358 intestinal barrier function Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 229940063675 spermine Drugs 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102100030234 Homeobox protein cut-like 1 Human genes 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 241000186606 Lactobacillus gasseri Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241001138501 Salmonella enterica Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000010227 enterocolitis Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000006547 fastidious anaerobe agar Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000000769 gas chromatography-flame ionisation detection Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 235000015141 kefir Nutrition 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 101100541106 Aspergillus oryzae (strain ATCC 42149 / RIB 40) xlnD gene Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 241001546092 Coprophilus Species 0.000 description 1
- 241001135265 Cronobacter sakazakii Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 101100208253 Dictyostelium discoideum tspA gene Proteins 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101710115755 Homeobox protein cut-like 1 Proteins 0.000 description 1
- 102100030231 Homeobox protein cut-like 2 Human genes 0.000 description 1
- 101000726740 Homo sapiens Homeobox protein cut-like 1 Proteins 0.000 description 1
- 101000726714 Homo sapiens Homeobox protein cut-like 2 Proteins 0.000 description 1
- 101000761460 Homo sapiens Protein CASP Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- 241001134659 Lactobacillus curvatus Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- GUNURVWAJRRUAV-UHFFFAOYSA-N N(1)-acetylspermine Chemical compound CC(=O)NCCCNCCCCNCCCN GUNURVWAJRRUAV-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 101000726742 Rattus norvegicus Homeobox protein cut-like 1 Proteins 0.000 description 1
- 241001237745 Salamis Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000607149 Salmonella sp. Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 1
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 101100113494 Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961) ctxB gene Proteins 0.000 description 1
- 206010051511 Viral diarrhoea Diseases 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940071604 biogaia Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000003965 capillary gas chromatography Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001517 counterregulatory effect Effects 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 244000000021 enteric pathogen Species 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 210000005205 gut mucosa Anatomy 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000004675 intestinal mucosal permeability Effects 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000003134 paneth cell Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000020200 pasteurised milk Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- -1 pentitol Chemical class 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000015175 salami Nutrition 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002470 solid-phase micro-extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004763 spore germination Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 101150089436 tcdB gene Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229950005578 tidiacic Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/061—Addition of, or treatment with, microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/061—Addition of, or treatment with, microorganisms
- A23C19/062—Addition of, or treatment with, microorganisms using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/02—Making cheese curd
- A23C19/05—Treating milk before coagulation; Separating whey from curd
- A23C19/054—Treating milk before coagulation; Separating whey from curd using additives other than acidifying agents, NaCl, CaCl2, dairy products, proteins, fats, enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A23Y2220/67—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Definitions
- the present invention relates to the field of microbiology and nutrition referring to Lactobacillus plantarum Inducia DSM21379 strain which has various applications in the field of biotechnology, food industry and medicine.
- probiotics are live microorganisms, which, when administered in adequate scientifically proven amounts, confer a health benefit on the host.
- Probiotic products may be conventional foods or dietary supplements.
- a probiotic product is a strain-specific preparation targeting several host functions (anti-infectious, morphologic, immunologic, metabolic) in order to improve health by either supporting host physiologic activity or by reducing the risk of disease.
- Probiotics are often used for enhancement of organisms' defense capability.
- Enhancement of organisms' natural immunity has become essential in connection with the ageing of population and diseases connected with immunodeficiency (HIV infection, tissue transplantation induced immunosuppression).
- HIV infection tissue transplantation induced immunosuppression
- the cause of all of mentioned diseases is the decrease of the capability of several physiological functions of the organism (Timiras, P. S. Physiology of aging: standards for age-related functional competence In: Comprehensive Human Physiology. Greger, R (edt)/Windhorst, U (eds) Springer Verlag, 1996; pp 2391-2405).
- Microbial metabolites play essential role in the integrity of mucosa, e.g. short chain fatty acids (SCFA), produced by lactic acid bacteria in the colon in the case of fiber (substances of plant origin) rich diet (Roy C C, Kien C L, Bouthillier L., Levy E. Short chain fatty acids: ready for prime time? Nutr. Clin. Pract., 2006; 21:351-366).
- SCFA short chain fatty acids
- Polyamines are linear aliphatic compound, in which amino acids are situated along the structure. Putrescine, spermidine and spermine belong to polyamines (Larque, M., Sabater-Molina, S. Zamora E. Biological significance of dietary polyamines. Nutrition 2007; 23(1): 87-95). Polyamines are produced by decarboxylation from amino acids ornithine and arginine. Putrescine is produced straight from ornithine; arginine, is primarily converted into agmantine which is then converted into putrescine (Halaris A, Plietz, Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs, 2007; 21: 885-90).
- Polyamines possess the ability to induce apoptosis, avoiding the hyperproliferation of epithelium and destruction of primary cancer cells (Moinard C, Cynober L, De Bandt J P Polyamines: metabolism and implications in human disease. Clin Nutr. 2005; 24: 184-197). Polyamines are produced endogenously or they are obtained actively from food.
- Lactobacilli comprise majority of microflora of the proximal colon. Lactobacilli produce polyamines through decarboxylation of amino acids, particularly at the high pH of the intestinal content (Lonvaud-Funel A, Biogenic amines in wine: role of lactic acid bacteria. FEMS Microbiol. Letters, 2001: 199: 9-13). On the other hand, strains of Lactobacillus acidophilus utilize putrescine and reduce odour of faces (WO 2008/019887, BASF AG).
- Probi AB Estonian patent EE03597 discloses pharmaceutical composition that contains L. plantarum strains 299 and 299v together with arginine for prevention translocation of intestinal microbes during liver injury. Also in this patent no information is available concerning the end products of arginine utilization (putrescine, cadaverine, tyramine, enhancement of NO or antioxidativity) by L. plantarum , which are responsible for aforementioned effect. In close relationship with previous patent another Probi AB patent EE04097 does not disclose the polyamines or NO production ability of mentioned L. plantarum strains.
- Lactobacillus rhamnosus GG could enhance NO production in the epithelial cells of the intestine or by proinflammatory cytokines and it has been indicated, that beneficial effects of Lactobacillus rhamnosus GG could be due to the production of NO by macrophages and epithelial cells (Korhonen K, Reijonen T M, Remes K, Malmstrom K, Klaukka T, Korppi M. Reasons for and costs of hospitalization for paediatric asthma: A prospective 1-year follow-up in a population-based setting. Pediatr Allergy Immunol 2001: 12:331-338).
- USA patent application US20060078595 discloses method to avoid the excessive permeability of the intestinal barrier in newborns by glutamate and its precursors as well as by polyamines spermidine, spermine, putrescine in the case of different syndromes (malnutrition, allergy, sepsis, translocation of microbes, endotoxemia, viral diarrhoea). Lactobacillus Reuteri (BIOGAIA) served as glutamate source.
- BIOGAIA Lactobacillus Reuteri
- Polyamine spermidine has inflammation-lowering property. It has been demonstrated that spermidine, when added to human monocytes stimulated with lipopolysaccharides, inhibits effectively the synthesis of TNF, IL-1, IL-6 and other proinflammatory cytokines (Zang M, Caragine T. Wong H et al. Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counter regulatory mechanism, that restrains the immune response. J. Exp. Med., 1997, 185: 1759-1768). Matsumoto with co-authors described the suppression of proinflammatory cytokine synthesis (Matsumoto M, Ohisshi H, Benno Y Impact of LKM512 yoghurt on improvement of intestinal environment of the elderly.
- Bifidobacterium lactis LKM512 comprising yoghurt administration to elderly decreased the glukoprotein haptoglobuline caused inflammatory acute phase response due to IL-1, 11-6 and TNF-alfa, but the probiotic administration was also accompanied by decrease of mutagenicity of the intestinal epithelial cells.
- different lactic acid bacteria incl. lactobacilli species and strains differ by their ability to induce pro- and anti-inflammatory cytokines and non-specific cellular immune response.
- Lactobacillus plantarum is a widely spread representative of the genus Lactobacillus .
- Aforementioned lactobacillus species is present on fermented plants (sauerkraut, pickles, and silage), fermented dairy/meat products (cheese, salami) as well as in human gastrointestinal tract. Lactobacillus plantarum is able to reorganize its metabolism according to environmental conditions.
- Probiotic Lactobacillus plantarum is available in probiotic foods as well as in food supplements (e.g. Lactobacillus plantarum 299v DSM 9843, Probi AB, Sweden, Sk ⁇ nemejeriers' ProViva probiotic brand in Sweden or as one of the components in bacterial composition VSL#3 (VSL Pharmaceuticals, Inc. USA).
- WO2007/108764 discloses the action mechanisms of Lactobacillus plantarum strains, which are able to enhance immunotolerance in the case on autoimmune coeliac disease.
- putrescine with lactobacilli, bifidobacteria and propionibacteria from Gouda cheese milk ultrafiltration are either polymerization reactions for incorporating putrescine into casein or vice versa—purification of these compounds by ultrafiltration, that have already been produced into milk, methods are different from this one described in present invention, where putrescine, that has been produced by lactobacilli into milk is still present in cheese after 30 days of ripening.
- lactobacillus paracasei Lactobacillus curvatus
- lactobacillus curvatus which are able to gain energy for proliferation from ornithine (ornithine is released from milk casein arginine) after depletion of carbohydrates
- LDL-c low density lipoprotein-cholesterol
- LDL-c particles carry cholesterol, triglycerides, fat-soluble vitamins and antioxidants.
- the LDL-cholesterol is an important modulator for prevention of atherosclerosis and maintenance of cardiovascular health.
- the LDL-c is widely recognized as an established cardiovascular risk marker.
- the close relation between mucosal epithelial cells of host gut and microbiota is of utmost importance for health.
- BHS bile salt hydrolases
- Lactobacillus spp strains are strain-specific and dependant on the origin and properties of a certain strain (Tanaka, H., K. Doesburg, T. Iwasaki and I. Mireau, Screening of lactic acid bacteria for bile salt hydrolase activity. J. Dairy Sci. 1999; 82: 2530-2535).
- the colonic microbiota is well stabilised and due to mucosal microbiota it does not change easily. But it is well known that the application of broad-spectrum antimicrobial preparations for treatment of infections and inflammatory complications may cause profound imbalance among GI microbiota.
- Clostridium difficile was identified in the 1970's as the causative agent of antibiotic associated diarrhoeae.
- the anaerobic spore-forming intestinal pathogen Clostridium difficile is spread in hospitals and elderly homes (Britton, R. A., Young, V. B. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 2012; 20, 313-319).
- C. difficile infection is initiated by infection with C. difficile spores. Endospore production is vital for the spread of Clostridium difficile infection. In order to cause disease, these spores must germinate and return to vegetative cell growth (Burns D. A, Heap J. T. Minton N. P.
- Clostridium difficile spore germination an update. Res Microbiol. 2010; 161(9):730-4). C. difficile elicits disease through the actions of secreted toxins, which are produced by vegetative cells, not by spores.
- C. difficile -associated diarrhea increases mortality rates, lengthens hospitalization and dramatically increases overall health care costs.
- CDAD C. difficile -associated diarrhea
- Clostridium difficile infection recurs in about 20% of patients, and increases to 40% and 60% with subsequent recurrences (Kelly, C. P., LaMont, J. T. Clostridium difficile -more difficult than ever. N Engl J Med. 2008; 359, 1932-1940).
- Antimicrobial treatment disrupts the complex balance of diverse microorganisms and is a key factor in the pathogenesis of C. difficile colonization and disease. Preservation and restoration of the microbial diversity could represent novel strategies.
- probiotics for prevention of CDI include combination L. acidophilus and L. casei, S. boulardii , or L. rhamnosus .
- a dosage of >10 9 cfu/day is more effective than lower doses.
- the antimicrobial activity of probiotic strains is one of the suggested mechanisms for competition with C. difficile .
- Lactic acid bacteria produce short chain fatty acids that lower the pH of the local gut environment as well as prevent the adhesion of C. difficile (McFarland, L. V., Beneda, H. W., Clarridge, J. E., Raugi, G. J. Implications of the changing face of C. difficile disease for health care practitioners. Am J Infect Control. 2007; 35, 237-253).
- the possibility for intestinal barrier protection with probiotics may result in interfering with the binding of C. difficile toxins A and B to colonic epithelial cells thus stabilizing gut permeability and inhibiting development of pseudomembranes on epithelia of gut.
- Lactobacilli is an important factor to take into consideration when looking for potential probiotics in the prevention of C. difficile infection or binding the C. difficile toxins (Tejero-Sarinena S., Barlow J., Costabile A, Gibson G. R., I. Rowland Antipathogenic activity of probiotics against Salmonella Typhimurium and Clostridium difficile in anaerobic batch culture systems: Is it due to synergies in probiotic mixtures or the specificity of single strains? Anaerobe 2013: 24; 60-65).
- CDI Clostridium difficile associated diarrhea
- Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients PLACIDE: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2013: 382, 1249-1257). After years of trials with different probiotics for treatment of CDI the strain, dose, and duration of probiotics are still under discussion (Naaber, P., Mikelsaar, M., Interactions between Lactobacilli and antibiotic-associated diarrhea. Adv Appl Microbiol, 2004: 54, 231-260).
- Xylitol is a 5-C sugar alcohol, e.g. pentitol, and is found in plants, fungi and algae.
- Xylitol is an important intermediate product in mammalian carbohydrate metabolism; i.e. human blood contains up to 8 ⁇ 10 ⁇ 5 M of xylitol. Consumed xylitol is not absorbed completely and the unabsorbed part can be used as a dietary fibre for bacterial fermentation to convert xylitol to short fatty acid chains utilized in energy pathways.
- Xylitol influences the growth of some species of gut microbiota in the large intestines stimulating the growth and activities of indigenous microbiota.
- xylitol contains 2.4 kcal as compared to one gram of glucose which has 3.87 kcal.
- Xylitol is advertised as “safe” for diabetics and individuals with hyperglycaemia (Talbot J. M., K. P. Fisher The Need for Special Foods and Sugar Substitutes by Individuals with Diabetes Mellitus. Diabetes Care 1978: 1; 231-240).
- the purpose of the present invention is to provide a strain Lactobacillus plantarum Inducia DSM 21379 for use as hypocholesterolemic agent for decreasing the level of LDL-cholesterol in blood for preventing the cholesterol metabolism disorders and consecutive cardiovascular disorders.
- Another purpose of the instant invention is to provide the aforesaid strain for use as an antimicrobial agent for lowering risk of Clostridium difficile associated diarrhoeae (CDAD) by preventing germination of Clostridium difficile spores and by suppressing proliferation of Clostridium difficile vegetative cells.
- CDAD Clostridium difficile associated diarrhoeae
- the next purpose of this invention is to provide Lactobacillus plantarum Inducia DSM 21379 for use as anti-oxidative agent for enhancing anti-oxidative activity of blood by reducing the level of oxidized low density lipoprotein (ox-LDL) and by enhancing the total anti-oxidative activity (TAA) of a composition comprising said strain.
- ox-LDL oxidized low density lipoprotein
- TAA total anti-oxidative activity
- the current invention also relates to the compositions comprising L. plantarum Inducia DSM 21379 for decreasing the levels of LDL-cholesterol and ox-LDL in blood, lowering risk of CDAD and for enhancing the natural defense potential and cellular immunity of a human.
- L. plantarum Inducia DSM 21379 produces polyamines from ornithine and glutamate, nitric mono-oxide (NO), the composition comprising said strain possesses antioxidative activity and improves the intestinal barrier function, increases the number of immunocytes in blood and induces cytokine synthesis for enhancement of organisms' natural defense.
- Lactobacillus plantarum Inducia DSM 21379 is used as enhancer of the natural defense potential and cellular immunity of a subject, and simultaneously as anti-oxidative agent as well as hypocholesterolemic agent.
- the composition may further comprise xylitol.
- the composition can be used for the production of food products, food supplements or pharmaceutical or veterinary products.
- the food product can be dairy product (fermented milk, cheese) or meat product, sweets, etc.
- the food supplement may be may be used in powder (capsules, lozenges, tablets, powder sachets etc.) or liquid (ampoules) form.
- the strain may be used in compositions in freeze-dried form.
- Lactobacillus plantarum Inducia DSM 21379 expresses in vitro on MRS agar medium antagonistic activity against several enteric pathogens (Table 1).
- Lactobacillus plantarum Inducia DSM 21379 antimicrobial activity against pathogens and non-starter lactobacilli on modified MRS agar medium (pathogen growth inhibition zone, mm) Pathogen Growth inhibition zone (mm) Non-starter lactobacilli (NSLAB) 2.67 ⁇ 3.4 Listeria monocytogenes 22.7 ⁇ 2.4 Yersinia enterocolitica 11.2 ⁇ 2.7 Salmonella enteritidis 22.1 ⁇ 1.9 S.
- Lactobacillus plantarum Inducia DSM 21379 antimicrobial activity in vitro in streak-line procedure was highest against E. coli , followed by growth inhibition of Salmonella sp., Shigella and Listeria . The lowest antimicrobial activity was detected against other lactobacilli (NSLAB).
- TAA and TAS of the microbial cells were incubated in MRS broth (Oxoid, U.K.) for 24 h at 37° C. Microbial cells were harvested by centrifugation (1500 RPM, during 10 min) at 4° C. and the pellet was washed with isotonic saline (4° C.) and suspended in 1.15% KCl (Sigma, USA). The density of the suspension was OD 600 of 1.1 ⁇ 10 9 bacterial cells ml ⁇ 1 ). Total antioxidative activity (TAA) was assessed by using the linolenic acid test (LA-test).
- LA-test linolenic acid test
- Nitrogen mono-oxide production measurements were carried out with 24 h old intact cells in 500 ⁇ of MRS broth with Apollo 4000 free radical analyzer (WPI, Berlin, Germany) and electrodes of type. ISO-NOP electrode signals were registered during 5-7 minutes. Mean signal strength was calculated. Each experimental point was measured in 4 independent parallels and each parallel was measured twice. NO concentration was calculated according to the standard curves correlation with the strength of the electrodes signal.
- Microbial strains were suspended in physiological saline according to McFarlandi turbidity standard (10 9 CFU/ml) and 0.5 ml of each strain suspension was seeded into decarboxylation medium (a 4.5 ml) and incubated at 37° C. for 4 days (Bover-Cid and Holzapfel W. H. Improved screening procedure for biogenic amine production by lactic acid bacteria. Int J food Microbiol 1999; 53, (1); 33-41(9)).
- Lactobacillus plantarum strain Inducia DSM 21379 is able to produce cadaverine from arginine, putrescine both from glutamine as well as from ornithine. But the control strain was able to produce putrescine in low amounts only from ornithine ( FIG. 1 ). Traces of cadaverine were detected both in control strain as well as in Lactobacillus plantarum Inducia DSM 21379. No histamine production was detected (Table 4).
- FIG. 1 Production of polyamines by L. plantarum DSM 21379 in vitro in the decarboxylation medium (Arena, M. E. and Manca de Nadra, M. C. Biogenic amine production by Lactobacillus . J Appl Microbiol, 2001; 90; 158-162) (a) from ornithine (b) from glutamine.
- FIG. 2 a , 2 b , 2 c Lactobacillus species by Pearson UPMAG cluster analyses in L. plantarum Inducia DSM 21379 group.
- FIG. 3 The pH values of in L. plantarum Inducia DSM 21379 in xylitol containing and control modified MRS media in microaerobic and anaerobic environment.
- FIG. 4 Presence of toxA and B genes in C. difficile VPI 10643 by reverse transcription (RT) and real-time PCR amplification (qPCR).
- FIG. 5 Presence of toxB gene in liver and small intestine of a hamster treated with ampicillin and C. difficile by reverse transcription (RT) and real-time PCR amplification (qPCR).
- RT reverse transcription
- qPCR real-time PCR amplification
- FIG. 6 a) Normal mucosa of large intestine after probiotic administration and b) mucosa with C. difficile infection.
- FIG. 7 Morphological changes in experimental CDAD infection. Moderate hyperaemia in a) small intestine and b) large intestine and intense hyperaemia in c) pancreas and d) spleen. Pseudomembrane in e) small intestine and PMN infiltration with pseudomembrane f) in large intestine.
- Microorganism Lactobacillus plantarum Inducia DSM 21379 was added to the cheese milk of Dairy Cooperative E-Piim, (inoculation dose 3 ⁇ 10 8 CFU/vat) and the milk was renneted (25 min). The curds were cut (25 min), heated (34° C. 15 min), dried (25 min), pressed, drained (1 h), salted in brine (12° C.; 20% NaCl; pH 4.7) 20 h, drained and dried (8 h), backed into plastic and ripened at 12° C. for at least 4 weeks.
- putrescine and tyramine were related to that: in different lots in comparison with control-cheese putrescine content increased 3-11 times and tyramine content accordingly 2-5 times.
- Lactobacillus plantarum Inducia DSM 21379 belongs to the facultatively heterofermentative group of lactobacilli and therefore the content of tyramine in cheeses was significantly lower than that of strains of OHEL group. On the other hand, the content of putrescine was higher.
- Permitted concentration of tyramine in food e.g. in cheese is 200 mg/kg (Karovicova and Kohajdova. Biogenic amines in food. Chem pap. 2005; 59 (1); 70-79; Larque, M., Sabater-Molina, S. Zamora E. Biological significance of dietary polyamines. Nutrition 2007; 23(1): 87-95). Tyramine is considered toxic in concentrations of 1000-8000 mg/kg.
- Putrescine is considered toxic if detected in organism in concentration of 2000 mg/kg per body weight and total toxicity of polyamines is >300 mg/kg per food product (Larque, M., Sabater-Molina, S. Zamora E. Biological significance of dietary polyamines. Nutrition 2007; 23(1): 87-95).
- Lactobacillus plantarum Inducia DSM 21379 comprising cheese the subject gets ca 3 mg of putrescine.
- the concentration is up to 50 ⁇ g per kg, which does not express toxic effect.
- mice consumed different cheeses during 30 days (control cheese with no additives, Lactobacillus plantarum strain Inducia DSM 21379 2 ⁇ 10 8 cfu/g comprising cheese).
- mice stayed in good condition, no changes in fur and digestion was detected.
- the mice were sacrificed by cervical dislocation at day 30. No translocation of lactobacilli or other bacteria of the microflora to blood or organs was detected at the autopsy.
- Tissue samples from the liver, spleen, ileum and colon were fixed in formalin and embedded in paraffin.
- Microtome-cut tissue samples were stained with hematoxyline-eosine.
- mice organs after administration of Lactobacillus plantarum Inducia DSM 21379 comprising cheese.
- Mice group Liver Spleen Ileum Colon L. plantarum Hyperaemia ii Lymph Lymph Inducia 6/10* follicles follicles DSM 21379 6/10* 8/10* comprising cheese consumed animals Control cheese Hyperaemia Hyperaemia Lymph Lymph consumed animals 3/10* 1/10 follicles follicles 3/10* 4/10* *p ⁇ 0.05
- Lactobacillus plantarum Inducia DSM 21379 comprising cheese during 1 month enhanced liver hyperemia and raised significantly lymphatic follicles (immunocytes) of mice ileum and colon in comparison with control mice. These results refer to enhancement of the defense capability of intestinal mucosa and liver functions.
- the double-blind placebo-controlled (DBPC) cross-over exploratory trial (International registration number ISRCTN38739209) was conducted according to the guidelines of Declaration of Helsinki. The trial was approved by the Ethics Review Committee on Human Research of the University of Tartu, Estonia (approval number 158/10, 26.03.2007). All participants signed their written informed consent at the enrollment and were given the possibility to withdraw from the study any time.
- DBPC placebo-controlled
- the clinical trial with healthy volunteers evaluated the impact of putrescine, NO and antioxidative compounds producing Lactobacillus plantarum Inducia DSM 21379 comprising food consumption on (Estonian cheese) 1) safety for the consumer; 2) humoral and cell immunity parameters of blood; 3) effect on intestinal microflora; 4) and urine metabolites, to detect possible health-promoting effects.
- the study group consisted of healthy volunteers, both male and female (M/F 4/8) aged 20-48 years.
- diabetes glucose and glycohemoglobin HbA1c from blood sera were detected.
- the trial was randomized double-blind cross-over study. Trial started with 3-week consumption of test cheese. Volunteers consumed the test cheese for 3 weeks. After a 2-week washout period, volunteers were crossed over to another 3 weeks of control cheese administration.
- Lactobacillus plantarum Inducia DSM 21379 content in 30 old test cheeses was 6 ⁇ 10 7 cfu/g.
- test cheese Before consumption the test cheese was incubated with Lactobacillus plantarum Inducia DSM 21379 for 30 days at 12° C. Regular Estonian cheese of Edam type without Lactobacillus plantarum Inducia DSM 21379 served as a control.
- the trial was a randomized blinded cross-over placebo controlled trial. Trial started with 3-week consumption of test cheese, followed by 2 week washout period, after which the control cheese was consumed for 3 weeks. Dose 50 g/day.
- Lactobacillus plantarum Inducia DSM 21379 comprising cheese had no negative impact on organisms' kidney and liver function nor affected according parameters (ASAT, ALAT albumine, blood sera creatinine).
- Lactobacillus plantarum DSM 21379 comprising cheese does not cause systemic inflammation, allergic sensibilisation or causes harm to essential organs.
- Microbial DNA was isolated from cheese by QIAamp DNA Mini Kit (QIAGEN) and amplified with primers Uni-515-GC-rev (ATCGTATTACCGCGGCTGCTGGCA-GC), Lab-159-f (GGAAACAGA/GTGCTAATACCG) (Hilor H G, Zoetendal E G, Vaughan E E, Marteau P, Akkermans, A D L, de Vos W M, /et al./ Molecular diversity of / Lactobacillus / ssp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA. /Appl Envir Microbiol /2002; 68: 114-123).
- Lactobacillus plantarum Inducia DSM 21379 comprising cheese changed lactobacilli pattern profile in feces in 5 persons of 12. These changes remained stable in 3 persons of 5 even 2 weeks after completing the trial.
- Lactobacillus plantarum Inducia DSM 21379 comprising cheese affects the composition of human intestinal lactoflora.
- Enhancement of parameters of cellular immunity is in accordance with results on animal model described above; where the administration of Lactobacillus plantarum Inducia DSM 21379 induced significantly Peyer's patches i.e. lymph follicles in the intestine. In these follicles interaction of the components of the immune system occurs.
- Proinflammatory cytokines incl. induction of IL-6 play important role in activation of TH1 type lymphocytes against bacteria through which macrophages i.e. blood monocytes are retroactive activated. Thereupon blood monocytes produce also IL-6.
- the content of polyamines (putrescine, acetylputrescine and acetylspermidine) in urine increased after consumption of L. plantarum Inducia DSM 21379 comprising probiotic cheese.
- Lactobacillus plantarum strain Inducia DSM 21379 is able to produce putrescine in vitro as well as in cheese. Consumption of probiotic Lactobacillus plantarum Inducia DSM 21379 cheese elevated the content of acetylputrescine in urine of trial participants.
- Acetylputrescine represents a detoxified compound, elevated content of which proves putrescine production by Lactobacillus plantarum Inducia DSM 21379 in gastrointestinal tract of volunteers or absorption and metabolism of additional amounts of putrescine, consumed with cheese. On the other hand, this indicates the successful adaptational reaction of organism to deal with superfluous amounts of putrescine by excreting it with urine in acetylated form.
- the immunostimulative effect of putrescine produced by Lactobacillus plantarum Inducia DSM 21379 was confirmed by the correlation between blood cytokine IL-6 and the quantity of macrophages (monocytes), which in this case could be considered activated macrophages.
- the finding mentioned together with H 2 O 2 is essential for the organisms' defense against foreign cells (microbes, cancer cells).
- Physiological doses of putrescine occurring in the gut due to Lactobacillus plantarum Inducia DSM 21379 could theoretically enhance the regeneration of the epithelium of intestinal mucosa and apoptosis of old cells, thus avoiding the hyperproliferation of epithelium. These mechanisms ensure the barrier function of intestinal mucosa and protects against penetration of allergens.
- DSM 21379 cheese regulates the amount and activity of blood monocytes through IL-6 which finding together with lymph follicles (increase of carriers of cellular immunity) demonstrated in experimental animals improves the barrier function of intestinal mucosa and supports organisms' immunological defense functions.
- the double-blind placebo-controlled (DBPC) cross-over exploratory trial (International registration number ISRCTN68198472) was conducted according to the guidelines of Declaration of Helsinki. The trial was approved by the Ethics Review Committee on Human Research of the University of Tartu, Estonia (approval number 178/T-13 19.01.2009). All participants signed their written informed consent at the enrollment and were given the possibility to withdraw from the study any time.
- DBPC placebo-controlled
- the objective of the clinical trial was to assess the safety and effect on the intestinal microflora of healthy volunteers of the Lactobacillus plantarum Inducia DSM 21379 containing yoghurt.
- Test-yogurt contained Lactobacillus plantarum strain Inducia DSM 21379 (5 ⁇ 10 6 -10 7 cfu/ml). Yoghurt without probiotic additive served as control. The trial started 3 week consumption of test-yoghurt, followed by a two-week washout period, after that the participants consumed the control yoghurt for 3 weeks. The daily dose was 10 8 -5 ⁇ 10 9 cfu).
- L. plantarum Inducia containing yoghurt activated the monocyte chemoattractant protein, which demonstrates the increased immune activity.
- BSH Bile salt hydrolase
- Yoghurt preparation The probiotic yoghurt was developed from adjusted and pasteurized (+92 . . . +95° C. 5 min) cow milk using L. plantarum Inducia DSM 21379 (2 ⁇ 10 11 cfu/g) as an adjunct starter (inoculation dose 1 g/t). Shortly, the pasteurized milk was cooled to +35 . . . +43° C. before mixing with starter cultures and the probiotic strain. The milk was fermented until a pH 4.2 . . . 4.5 was reached and cooled to +23 . . . +27° C. The yoghurt was sweetened with 5% of sugar, packaged in plastic cups and cooled to +2 . . . +6° C. A yoghurt without probiotic adjunct served as a control.
- Body mass index was calculated as the weight (kg) divided by squared height (m 2 ). BMI was used to classify normal weight range (18.5-24.9 kg/m 2 ), overweight ( ⁇ 25.0 kg/m 2 ) and obesity ( ⁇ 30.0 kg/m 2 ) in healthy volunteers (WHO. The International Task Force. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation on Obesity. Geneva, Switzerland. WHO/Nut/NCD/98. 1998; 1).
- the samples of fasting blood were collected four times: at recruitment, after administration of either the L. plantarum Inducia DSM 21379 comprising product or control product, after wash-out period, and after the administration of the control or probiotic product at the end of the trial.
- Haematological indices plasma lipids: total cholesterol, LDL-cholesterol (LDL), HDL-cholesterol (HDL) and triglycerides were determined by standard laboratory methods using certified assays in the local clinical laboratory (United Laboratories of Tartu University Clinics, Estonia). Intervals for routine laboratory tests proposed by Nordic Reference Interval Project (NORIP, Rustard P., Felding P., Franszon L., Kairisto V., Lahti A., Martensson A., Hyltoft Petersen P., Simonsson P., Steensland H., Uldall A. (2004) The Nordic Reference Interval Project 2000: recommended reference intervals for 25 common biochemical properties. Scand J Clin Lab Invest 64: 271-284) were used as reference.
- L. plantarum Inducia DSM 21379 consumption were revealed in the content of LDL-cholesterol particles.
- the LDL-cholesterol content was decreased after consumption of L. plantarum Inducia DSM 21379 comprising yoghurt (Table 15).
- the purpose of the study was to assess the antagonistic activity of L. plantarum Inducia DSM 21379 against C difficile reference strains in anaerobic environment.
- the tested strains were: L. plantarum Inducia DSM 21379 and C. difficile VPI 10463 (ATCC 43255), M 13042 hypervirulent strain.
- bacteriological seedings for growth were performed (0.1 ml) to MRS and LAB160 media.
- the plates were incubated in anaerobic and microaerobic conditions.
- the growth was checked after 2-5 days and the results were expressed as log 10 CFU/ml.
- L. plantarum Inducia DSM 21379 Complete suppression of C. difficile vegetative cells by L. plantarum Inducia DSM 21379 was discovered after co-cultivation in BHI medium further seeded on selective MRS and CD LAB180 media after 48 h incubation L. plantarum Inducia DSM 21379 showed the highest values at 24 h in the BHI medium. After 48 h the growth yield of L. plantarum Inducia DSM 21379 was modestly suppressed equally in single culture (6.3 log cfu/g) or if combined with C. difficile strains (7.3 and 6.0 log cfu/g).
- the purpose of the following in vitro experiment was to determine the antimicrobial effect of L. plantarum Inducia DSM 21379 vegetative cells of on reference and clinical C. difficile strains.
- the distinction between the suppressive effect of natural (acidic) and neutralised supernatant (inhibitory substances e.g. peptides) of L. plantarum Inducia DSM 21379 helps to discriminate between two mechanisms—either impact of organic acids or presence of bacteriocins.
- the L. plantarum Inducia DSM 21379 was maintained at ⁇ 80° C. in microtubes on glass-beads and was activated trice in MRS broth with 0.15% agar, incubated under microaerobic conditions (10% CO 2 ) at 37° C. for 24 h. Overnight L. plantarum Inducia DSM 21379 culture was used to inoculate BHI broth 1% v/v and was incubated in microaerobic conditions for 24 h.
- the extracellular cell free supernatant (CFS) was collected by centrifugation from a 24 h old BHI broth cultures. The pH of cell free supernatant was measured and divided in half. The on half was left acidic and the other half was neutralized with 6N NaOH to pH 6.0, the both supernatants were filter sterilized.
- C. difficile strains were maintained at ⁇ 80° C. in microtubes on glass-beads and were activated trice on Fastidious Anaerobe Agar (FAA) with horse blood supplement for 24 h in anaerobic milieu (Anaerobic glove box, gases 90% N:5% CO 2 :5% H 2 ). Overnight C. difficile cultures were used for the suspension with density according to MacFarland 3.0. For evaluating the antimicrobial activity of L. plantarum Inducia DSM 21379, 20 ⁇ l of C.
- FAA Fastidious Anaerobe Agar
- the suppressive activity of L. plantarum Inducia DSM 21379 was tested with Kruskal-Wallis test, where the growth density (OD 620nm ) of C. difficile control was compared with the data of C. difficile growth density in natural and neutralised and in supernatants dilutions. The statistical analysis of data was performed using PAST Statistics Web provided program.
- C. difficile CDE C. difficile CDE
- CDP 1-9 reference strains: C. difficile VPI 10463 (ATCC 43255) and C. difficile M13042 (epidemic strain from Canada belonging to ribotype 027).
- strain L. plantarum Inducia DSM 21379 possess antimicrobial activity against C. difficile relying both on acid production in natural product (pH lowering) and in a smaller extent also on some antimicrobial protein-like substance still active after neutralisation of the supernatant (neutralized product) (Table 17).
- the purpose of the study was to find if xylitol influences the antagonistic activity of L. plantarum Inducia DSM 21379 against C. difficile.
- Inducia (10 5 cfu/ml) was incubated in MRS media where glucose was substituted for 5% xylitol or used without sugar in microaerobic and anaerobic environment. The count of lactobacilli was registered as cfu/ml of media. We tested at 2, 6, 24, and 48 h if L. plantarum Inducia DSM 21379 uses xylitol for growth in vitro in microaerobic and anaerobic conditions.
- the purpose of the study was to measure the use of xylitol by L. plantarum Inducia DSM 21379 in microaerobic and anaerobic environments.
- Double experiments were performed by cultivation of L. plantarum Inducia DSM 21379 in in MRS medium with 5% xylitol in microaerobic and anaerobic environments for 2 to 120 h.
- Xylitol was detected with mass spectrometry QTRAP 3200 (Applied Biosystems, USA).
- the samples were centrifuged 3 min 10000 g, diluted 100 folds and 50 ⁇ l was mixed with 50 ⁇ l internal standard (5 mM D4-succinic acid in acetonitrile, 50 ⁇ l). 5 ⁇ l of dilutions were injected into mass spectrometry using 50% acetonitril/water eluent.
- the substrates were identified by multiple reaction monitoring (MRM) ionpairs 151/101 (xylitol) and 121/77 (internal standard). Concentration was calculated from a calibration curve made from solutions with known concentrations of commercial xylitol (Sigma-Aldrich, Germany).
- MRM multiple reaction monitoring
- the purpose of the study was to mimic in vitro the gut environment similar to elaborated C. difficile infection model in Syrian hamsters.
- the L. plantarum Inducia DSM 21379 and the two reference strains of C. difficile increased the number of CFU nearly for 2 to 4 logarithms after 48 h of cultivation in the control media of BHI. No changes were seen after influencing C. difficile strains with xylitol and ampicillin (Table 20).
- the purpose of the study was to assess the growth of L. plantarum Inducia DSM 21379 and C. difficile reference strains by co-cultivation at different concentrations of xylitol and ampicillin.
- the BHI media supplemented with 5% xylitol and 0.75 ⁇ l/ml ampicillin were applied for co-cultivation of L. plantarum Inducia DSM 21379 and C. difficile reference strains in anaerobic environment (workstation Concept 400, UK) for 24 and 48 h.
- L. plantarum Inducia DSM 21379 , C. difficile VPI and M reference strains after cocultivation were tested as single in BHI media with ampicillin and xylitol 5% (1, 2a, 2b). After ten-fold serial dilutions for determining the count of L. plantarum Inducia in MRS broth was cultivated in CO 2 environment and for C. difficile on LAB 160 media in anaerobic milieu.
- the purpose of the study was to assess the influence of L. plantarum Inducia DSM 21379 on Clostridium difficile reference strain VPI 10463 caused infection in the intestinal tract of C. difficile spores challenged hamsters.
- L. plantarum Inducia was high in jejunum (range 0-6.0, median 4.0 CFU log 10/g and in ileum 6.0-7.6, median 6.7).
- L. plantarum Inducia DSM 21379 acted seemingly via its acid production through its SCFAs profile.
- the typical CDAD infection was modelled in hamster model as in C. difficile infection the toxin damage of organs is the leading pathogenetic modulator.
- the severe enterocolitis developed the infiltration with red blood cells and polymorphonuclear leukocytes into gut mucosa, liver and spleen resulted in death of animals. In organs the hyperemia was present ( FIG. 7 a - f ).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
- This application is a continuation-in-part and claims the benefit under 35 U.S.C. §120 of U.S. application Ser. No. 12/992,862, filed Nov. 15, 2010, the entire contents of which are incorporated herein by reference, which is a 371 National Stage of International Application No. PCT/EE2009/000006, filed May 12, 2009, the entire contents of which are incorporated herein by reference, which claims priority from prior EE Application No. P200800027, filed May 13, 2008.
- The present invention relates to the field of microbiology and nutrition referring to Lactobacillus plantarum Inducia DSM21379 strain which has various applications in the field of biotechnology, food industry and medicine.
- During the past decades lactobacilli have widely been used as probiotics in functional foods. Food can be regarded as functional, if beyond adequate nutritional components it contains some natural additives (pre- or probiotics), which beneficially affect one or more target functions in the body, either improving the state of health and well-being and/or reducing disease risk. Probiotics are live microorganisms, which, when administered in adequate scientifically proven amounts, confer a health benefit on the host. Probiotic products may be conventional foods or dietary supplements. Currently a probiotic product is a strain-specific preparation targeting several host functions (anti-infectious, morphologic, immunologic, metabolic) in order to improve health by either supporting host physiologic activity or by reducing the risk of disease.
- Probiotics are often used for enhancement of organisms' defense capability.
- Enhancement of organisms' natural immunity has become essential in connection with the ageing of population and diseases connected with immunodeficiency (HIV infection, tissue transplantation induced immunosuppression). The cause of all of mentioned diseases is the decrease of the capability of several physiological functions of the organism (Timiras, P. S. Physiology of aging: standards for age-related functional competence In: Comprehensive Human Physiology. Greger, R (edt)/Windhorst, U (eds) Springer Verlag, 1996; pp 2391-2405).
- The permeability of the intestinal mucosa frequently increases on the background of chronic inflammation. Microbial metabolites play essential role in the integrity of mucosa, e.g. short chain fatty acids (SCFA), produced by lactic acid bacteria in the colon in the case of fiber (substances of plant origin) rich diet (Roy C C, Kien C L, Bouthillier L., Levy E. Short chain fatty acids: ready for prime time? Nutr. Clin. Pract., 2006; 21:351-366).
- For enhancement of mucosal barrier besides short chain fatty acids also polyamines are essential. Polyamines are linear aliphatic compound, in which amino acids are situated along the structure. Putrescine, spermidine and spermine belong to polyamines (Larque, M., Sabater-Molina, S. Zamora E. Biological significance of dietary polyamines. Nutrition 2007; 23(1): 87-95). Polyamines are produced by decarboxylation from amino acids ornithine and arginine. Putrescine is produced straight from ornithine; arginine, is primarily converted into agmantine which is then converted into putrescine (Halaris A, Plietz, Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs, 2007; 21: 885-90).
- The physiological impact of polyamines is targeted to cell growth and differentiation, regulation of immune cells and inflammatory response, and several other effects. Polyamines possess the ability to induce apoptosis, avoiding the hyperproliferation of epithelium and destruction of primary cancer cells (Moinard C, Cynober L, De Bandt J P Polyamines: metabolism and implications in human disease. Clin Nutr. 2005; 24: 184-197). Polyamines are produced endogenously or they are obtained actively from food.
- In the case of the damage of epithelial cells, the production of polyamines by the intestinal microflora is considered one of the compensatory mechanisms for modification of immune response and apoptosis regulation. Lactobacilli comprise majority of microflora of the proximal colon. Lactobacilli produce polyamines through decarboxylation of amino acids, particularly at the high pH of the intestinal content (Lonvaud-Funel A, Biogenic amines in wine: role of lactic acid bacteria. FEMS Microbiol. Letters, 2001: 199: 9-13). On the other hand, strains of Lactobacillus acidophilus utilize putrescine and reduce odour of faces (WO 2008/019887, BASF AG).
- Probi AB Estonian patent EE03597 discloses pharmaceutical composition that contains
L. plantarum strains 299 and 299v together with arginine for prevention translocation of intestinal microbes during liver injury. Also in this patent no information is available concerning the end products of arginine utilization (putrescine, cadaverine, tyramine, enhancement of NO or antioxidativity) by L. plantarum, which are responsible for aforementioned effect. In close relationship with previous patent another Probi AB patent EE04097 does not disclose the polyamines or NO production ability of mentioned L. plantarum strains. - It has been demonstrated, that Lactobacillus rhamnosus GG could enhance NO production in the epithelial cells of the intestine or by proinflammatory cytokines and it has been indicated, that beneficial effects of Lactobacillus rhamnosus GG could be due to the production of NO by macrophages and epithelial cells (Korhonen K, Reijonen T M, Remes K, Malmstrom K, Klaukka T, Korppi M. Reasons for and costs of hospitalization for paediatric asthma: A prospective 1-year follow-up in a population-based setting. Pediatr Allergy Immunol 2001: 12:331-338). It has been demonstrated, that NO protects mucosa for damages and excessive permeability, arising after reperfusion (Payne D, Kubes P. Nitric oxide donors reduce the rise in reperfusion-induced intestinal mucosal permeability. Am J Physiol. 1993: 265 (1 Pt 1):G189-G195).
- USA patent application US20060078595 (Friesland Brands B.V.) discloses method to avoid the excessive permeability of the intestinal barrier in newborns by glutamate and its precursors as well as by polyamines spermidine, spermine, putrescine in the case of different syndromes (malnutrition, allergy, sepsis, translocation of microbes, endotoxemia, viral diarrhoea). Lactobacillus Reuteri (BIOGAIA) served as glutamate source.
- Polyamine spermidine has inflammation-lowering property. It has been demonstrated that spermidine, when added to human monocytes stimulated with lipopolysaccharides, inhibits effectively the synthesis of TNF, IL-1, IL-6 and other proinflammatory cytokines (Zang M, Caragine T. Wong H et al. Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counter regulatory mechanism, that restrains the immune response. J. Exp. Med., 1997, 185: 1759-1768). Matsumoto with co-authors described the suppression of proinflammatory cytokine synthesis (Matsumoto M, Ohisshi H, Benno Y Impact of LKM512 yoghurt on improvement of intestinal environment of the elderly. FEMS immunol. Medical Microbiol, 2001; 31:181-186). Bifidobacterium lactis LKM512 comprising yoghurt administration to elderly decreased the glukoprotein haptoglobuline caused inflammatory acute phase response due to IL-1, 11-6 and TNF-alfa, but the probiotic administration was also accompanied by decrease of mutagenicity of the intestinal epithelial cells. At the same time it is evident, that different lactic acid bacteria incl. lactobacilli species and strains differ by their ability to induce pro- and anti-inflammatory cytokines and non-specific cellular immune response. Up to now, no lactobacillus species/strain has been described, which would be able to produce physiologically relevant amounts of polyamines, which could be detected in urine after the consumption of this particular strain comprising composition and which promote simultaneously the adaptive activation of immunocytes due to interleukin IL-6.
- Proinflammatory cytokine IL-6 synthesis has been described after 24 h of stimulation with different strains of Bifidobacterium animalis and Lactobacillus rhamnosus (Miettinen M., Vuopio-Varkila J, Varkila K. Synthesis of human tumour necrosis factor alpha, interleukin-6 and interleukin-10 is induced by lactic acid bacteria. Infection and Immunity, 1996, 64:5403-5408). It is important to observe inflammation markers like counts of leucocytes (WBC) and amount of CRP in sera on the induction of IL-6 (Kiecolt-Glaser J K, Preacher K J, MacCallum R C et al. Chronic stress and age-related increases in the proinflammatory cytokine IL-6, PNAS, 2003; 100:9090-9095) to avoid the overproduction of IL-6. Aforementioned is associated with cardio-vascular diseases, arthritis, type II diabetes, cancer, periodontal diseases, cachexy and decrease of organisms functions (Rose-John S., J. Scheller, G. Elson, and S. A. Jones. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer J. Leukoc. Biol., Aug. 1, 2006; 80 (2): 227-236).
- Lactobacillus plantarum is a widely spread representative of the genus Lactobacillus. Aforementioned lactobacillus species is present on fermented plants (sauerkraut, pickles, and silage), fermented dairy/meat products (cheese, salami) as well as in human gastrointestinal tract. Lactobacillus plantarum is able to reorganize its metabolism according to environmental conditions.
- Probiotic Lactobacillus plantarum is available in probiotic foods as well as in food supplements (e.g. Lactobacillus plantarum 299v DSM 9843, Probi AB, Sweden, Skånemejeriers' ProViva probiotic brand in Sweden or as one of the components in bacterial composition VSL#3 (VSL Pharmaceuticals, Inc. USA). WO2007/108764 (Probac AB) discloses the action mechanisms of Lactobacillus plantarum strains, which are able to enhance immunotolerance in the case on autoimmune coeliac disease.
- Cheese as a probiotic carrier has several controversial aspects. Incorporation lactobacilli of human origin into a food product different from other milk-based products and having a long ripening period could be complicated. At the same time fat and protein-rich cheese matrix protects a probiotic microbial strain throughout the passage of gastrointestinal tract better than other milk products (yoghurt, kefir). Antimicrobial and antioxidative probiotic cheese has been produced by using Lactobacillus fermentum ME-3 (DSM 14241) (Estonian patent EE04580, Russian patent RU2284354, USA patent U.S. Pat. No. 6,190,879). European patent EP1064857B1 (Snow Brand Milk Products Co Ltd., 2004) discloses methods for production substances incl. putrescine with lactobacilli, bifidobacteria and propionibacteria from Gouda cheese milk ultrafiltration. These methods are either polymerization reactions for incorporating putrescine into casein or vice versa—purification of these compounds by ultrafiltration, that have already been produced into milk, methods are different from this one described in present invention, where putrescine, that has been produced by lactobacilli into milk is still present in cheese after 30 days of ripening. Various non-starter lactobacilli have been described (Lactobacillus paracasei, Lactobacillus curvatus), which are able to gain energy for proliferation from ornithine (ornithine is released from milk casein arginine) after depletion of carbohydrates (Laht T.-M., Kask S., Elias P., Adamberg K., Paalme T. Role of arginine in the development of secondary microflora in Swiss-type cheese. Int. Dairy Journal, 2002, 12: 831-840).
- Till now no lactobacillus species/strain have been described, the culture of which produces NO and additionally physiologically relevant amounts of polyamines in food product, whereas the latter could be detectable in urine after the consumption of this strain comprising food product (cheese) or composition and that is able to regulate through polyamines the apoptosis of intestinal epithelium and increase the count of the mucosal lymphfollicles and blood monocytes, regulating the condition of mucosa by NO and antioxidative compounds and to enhance the activation of immune cells particularly the activation of macrophages by central interleukine.
- One of the factors leading to cardiovascular disease (CVD) is abnormally elevated cholesterol level. Recently, the view of high cholesterol as damaging agent has been reverted to abnormality of its particles, particularly low density lipoprotein-cholesterol (LDL-c). LDL-c accounts 60-70% of total cholesterol. LDL-c particles carry cholesterol, triglycerides, fat-soluble vitamins and antioxidants. The LDL-cholesterol is an important modulator for prevention of atherosclerosis and maintenance of cardiovascular health. Thus, the LDL-c is widely recognized as an established cardiovascular risk marker. The close relation between mucosal epithelial cells of host gut and microbiota is of utmost importance for health. Among indigenous microbiota of gastrointestinal tract (GIT) the lactic acid bacteria assimilate cholesterol from dietary products (Gilliland, S. E., Nelson, C. R., Maxwell, C., Assimilation of cholesterol by Lactobacillus acidophilus. Appl Environ Microbiol 1985; 49, 377-381). In patent of Cuñé Castellana, 2009 (EP2485743B1; AB Probiotics S.A.) Lactobacillus plantarum strains CECT 7528, CECT 7526 and CECT 7529 as single or in composition demonstrated both in vitro and in vivo the cholesterol lowering ability. These strains have bile salt hydrolases (BHS) activity, also the antagonistic activity to inhibit the growth of pathogenic strains (Salmonella enterica Enteritidis, Salmonella enterica Typhimurium, Yersinia pseudotuberculosis, Clostridium perfringens, Clostridium ramnosus, Enterococcus faecalis) and can be used as probiotic bacteria.
- Pereira et al. (Pereira, D. I., McCartney, A. L., Gibson, G. R., An in vitro study of the probiotic potential of a bile-salt-hydrolyzing Lactobacillus fermentum strain, and determination of its cholesterol-lowering properties. Appl Environ Microbiol. 2003; 69, 4743-4752) have demonstrated the role of short-chain fatty acid concentrations, specifically the molar proportion of propionate and/or bile salt deconjugation as the major mechanism involved in the purported cholesterol-lowering properties of L. fermentum.
- However, the effect of Lactobacillus spp strains on levels of serum cholesterol (and cholesterol fractions) is strain-specific and dependant on the origin and properties of a certain strain (Tanaka, H., K. Doesburg, T. Iwasaki and I. Mireau, Screening of lactic acid bacteria for bile salt hydrolase activity. J. Dairy Sci. 1999; 82: 2530-2535).
- Disturbed Microbial Ecology of Gut
- The colonic microbiota is well stabilised and due to mucosal microbiota it does not change easily. But it is well known that the application of broad-spectrum antimicrobial preparations for treatment of infections and inflammatory complications may cause profound imbalance among GI microbiota.
- Clostridium difficile Infection
- Clostridium difficile was identified in the 1970's as the causative agent of antibiotic associated diarrhoeae. The anaerobic spore-forming intestinal pathogen Clostridium difficile is spread in hospitals and elderly homes (Britton, R. A., Young, V. B. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 2012; 20, 313-319). C. difficile infection is initiated by infection with C. difficile spores. Endospore production is vital for the spread of Clostridium difficile infection. In order to cause disease, these spores must germinate and return to vegetative cell growth (Burns D. A, Heap J. T. Minton N. P. Clostridium difficile spore germination: an update. Res Microbiol. 2010; 161(9):730-4). C. difficile elicits disease through the actions of secreted toxins, which are produced by vegetative cells, not by spores.
- In a quarter of patients (25%) infected with C. difficile develop serious sequela such as pseudomembraneous colitis (PMC). C. difficile-associated diarrhea (CDAD) increases mortality rates, lengthens hospitalization and dramatically increases overall health care costs. Clostridium difficile infection recurs in about 20% of patients, and increases to 40% and 60% with subsequent recurrences (Kelly, C. P., LaMont, J. T. Clostridium difficile-more difficult than ever. N Engl J Med. 2008; 359, 1932-1940). Antimicrobial treatment disrupts the complex balance of diverse microorganisms and is a key factor in the pathogenesis of C. difficile colonization and disease. Preservation and restoration of the microbial diversity could represent novel strategies. The crucial moment in prevention and treatment of this disease is to find the possibility to reconstitute the alteration of intestinal microbiota during and after antibiotic therapy with various regimens incl. administration of probiotics. Most probiotics colonize the gut temporarily, produce bactericidal acids and peptides and promote “competition” among microbes by competing for nutrients and epithelial adhesion. These effects appear to reduce the favourability of the environment for C. difficile. Previous studies suggest that probiotics for prevention of CDI include combination L. acidophilus and L. casei, S. boulardii, or L. rhamnosus. In addition, a dosage of >109 cfu/day is more effective than lower doses.
- The antimicrobial activity of probiotic strains is one of the suggested mechanisms for competition with C. difficile. Lactic acid bacteria produce short chain fatty acids that lower the pH of the local gut environment as well as prevent the adhesion of C. difficile (McFarland, L. V., Beneda, H. W., Clarridge, J. E., Raugi, G. J. Implications of the changing face of C. difficile disease for health care practitioners. Am J Infect Control. 2007; 35, 237-253). Next, the possibility for intestinal barrier protection with probiotics may result in interfering with the binding of C. difficile toxins A and B to colonic epithelial cells thus stabilizing gut permeability and inhibiting development of pseudomembranes on epithelia of gut.
- Strain-specificity of lactobacilli is an important factor to take into consideration when looking for potential probiotics in the prevention of C. difficile infection or binding the C. difficile toxins (Tejero-Sarinena S., Barlow J., Costabile A, Gibson G. R., I. Rowland Antipathogenic activity of probiotics against Salmonella Typhimurium and Clostridium difficile in anaerobic batch culture systems: Is it due to synergies in probiotic mixtures or the specificity of single strains? Anaerobe 2013: 24; 60-65).
- Furthermore, some clinical trials could not reach statistical evidence to demonstrate the effect for the prevention of Clostridium difficile associated diarrhea (CDAD) of certain probiotics. The authors of a large, randomized trial including 2941 elderly adults with antibiotic exposure noted that those who received probiotics (a multistrain preparation of Lactobacillus acidophilus and Bifidobacterium bifidum) did not show a risk reduction for CDI (RR 0.71; 95% CI 0.34-1.47; p=0.35) (Allen, S. J., Wareham, K., Wang, D., Bradley, C., Hutchings, H., Harris, W., Dhar, A., Brown, H., Foden, A., Gravenor, M. B., Mack, D. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2013: 382, 1249-1257). After years of trials with different probiotics for treatment of CDI the strain, dose, and duration of probiotics are still under discussion (Naaber, P., Mikelsaar, M., Interactions between Lactobacilli and antibiotic-associated diarrhea. Adv Appl Microbiol, 2004: 54, 231-260).
- Xylitol Application
- Xylitol is a 5-C sugar alcohol, e.g. pentitol, and is found in plants, fungi and algae. Xylitol is an important intermediate product in mammalian carbohydrate metabolism; i.e. human blood contains up to 8×10−5 M of xylitol. Consumed xylitol is not absorbed completely and the unabsorbed part can be used as a dietary fibre for bacterial fermentation to convert xylitol to short fatty acid chains utilized in energy pathways. Xylitol influences the growth of some species of gut microbiota in the large intestines stimulating the growth and activities of indigenous microbiota. One gram of xylitol contains 2.4 kcal as compared to one gram of glucose which has 3.87 kcal. Xylitol is advertised as “safe” for diabetics and individuals with hyperglycaemia (Talbot J. M., K. P. Fisher The Need for Special Foods and Sugar Substitutes by Individuals with Diabetes Mellitus. Diabetes Care 1978: 1; 231-240).
- In our previous studies on Caco-2 cell lines we have discovered that 1% xylitol prevented the adhesion of vegetative cells of C. difficile reference strain VPI 10463, seemingly blocking the receptors on cells. In an applied hamster model (Naaber, P., Lehto, E., Salminen, S., Mikelsaar, M Inhibition of adhesion of Clostridium difficile to Caco-2 cells. FEMS Immunol Med Microbiol. 1996: 14, 205-209) 1 ml of 20% xylitol solution together with Lactobacillus rhamnosus GG significantly protected animals from development of severe enterocolitis (Naaber, P., Lehto, E., Salminen, S., Mikelsaar, M., 1996. Inhibition of adhesion of Clostridium difficile to Caco-2 cells. FEMS Immunol Med Microbiol, 14, 205-209). In these experimental studies with xylitol in combination with probiotic L. rhamnosus GG the vegetative cells of Clostridium difficile, precultivated in laboratory anaerobic environment, have applied for inoculation of cell cultures or hamsters.
- In opposite, in clinical practice or elderly home the infection develops from inoculation with C. difficile extremely resistant spores surviving in the aerobic environment of these facilities. The spores start to germinate inside the intestine of host.
- Some authors have postulated that in the animal model some of sugars similarly to glucose could block the expression of toxins A and B of C. difficile (Karlsson, S., Burman, L. G., Akerlund, T. Induction of toxins in Clostridium difficile is associated with dramatic changes of its metabolism. Microbiology, 2008: 154, 3430-3436).
- There is still a need for probiotic strains effective in enhancing of cellular immunity, decreasing LDL-cholesterol as well as in lowering the risk of Clostridium difficile infection.
- The purpose of the present invention is to provide a strain Lactobacillus plantarum Inducia DSM 21379 for use as hypocholesterolemic agent for decreasing the level of LDL-cholesterol in blood for preventing the cholesterol metabolism disorders and consecutive cardiovascular disorders.
- Another purpose of the instant invention is to provide the aforesaid strain for use as an antimicrobial agent for lowering risk of Clostridium difficile associated diarrhoeae (CDAD) by preventing germination of Clostridium difficile spores and by suppressing proliferation of Clostridium difficile vegetative cells.
- The next purpose of this invention is to provide Lactobacillus plantarum Inducia DSM 21379 for use as anti-oxidative agent for enhancing anti-oxidative activity of blood by reducing the level of oxidized low density lipoprotein (ox-LDL) and by enhancing the total anti-oxidative activity (TAA) of a composition comprising said strain.
- The current invention also relates to the compositions comprising L. plantarum Inducia DSM 21379 for decreasing the levels of LDL-cholesterol and ox-LDL in blood, lowering risk of CDAD and for enhancing the natural defense potential and cellular immunity of a human.
- Due to the fact that L. plantarum Inducia DSM 21379 produces polyamines from ornithine and glutamate, nitric mono-oxide (NO), the composition comprising said strain possesses antioxidative activity and improves the intestinal barrier function, increases the number of immunocytes in blood and induces cytokine synthesis for enhancement of organisms' natural defense. Lactobacillus plantarum Inducia DSM 21379 is used as enhancer of the natural defense potential and cellular immunity of a subject, and simultaneously as anti-oxidative agent as well as hypocholesterolemic agent.
- The composition may further comprise xylitol. The composition can be used for the production of food products, food supplements or pharmaceutical or veterinary products. The food product can be dairy product (fermented milk, cheese) or meat product, sweets, etc. The food supplement may be may be used in powder (capsules, lozenges, tablets, powder sachets etc.) or liquid (ampoules) form. The strain may be used in compositions in freeze-dried form.
- The fact that the microbial strain originates from the intestinal tract of a healthy child proves its GRAS (generally recognized as safe) status i.e. that this strain of microorganism is harmless for human organism and is suitable for oral application compositions.
- Lactobacillus plantarum Inducia DSM 21379 expresses in vitro on MRS agar medium antagonistic activity against several enteric pathogens (Table 1).
-
-
TABLE 1 Lactobacillus plantarum Inducia DSM 21379 antimicrobial activity against pathogens and non-starter lactobacilli on modified MRS agar medium (pathogen growth inhibition zone, mm) Pathogen Growth inhibition zone (mm) Non-starter lactobacilli (NSLAB) 2.67 ± 3.4 Listeria monocytogenes 22.7 ± 2.4 Yersinia enterocolitica 11.2 ± 2.7 Salmonella enteritidis 22.1 ± 1.9 S. typhimurium 20.8 ± 2.8 Shigella sonnei 24.0 ± 0.1 Escherichia coli 23.0 ± 1.4 Enterobacter sakazakii 18.1 ± 1.8 Campylobacter jejuni 12.0 ± 7.6 - Lactobacillus plantarum Inducia DSM 21379 antimicrobial activity in vitro in streak-line procedure (antimicrobial effect of metabolites) was highest against E. coli, followed by growth inhibition of Salmonella sp., Shigella and Listeria. The lowest antimicrobial activity was detected against other lactobacilli (NSLAB).
- Total Antioxidative Activity of Lactobacillus plantarum Inducia DSM 21379
- Method. For the detection of TAA and TAS of the microbial cells, the strain L. plantarum Inducia was incubated in MRS broth (Oxoid, U.K.) for 24 h at 37° C. Microbial cells were harvested by centrifugation (1500 RPM, during 10 min) at 4° C. and the pellet was washed with isotonic saline (4° C.) and suspended in 1.15% KCl (Sigma, USA). The density of the suspension was OD600 of 1.1×109 bacterial cells ml−1). Total antioxidative activity (TAA) was assessed by using the linolenic acid test (LA-test). (Kullisaar, T, Songisepp, Mikelsaar M, Zilmer, K, Vihalemm, T, Zilmer, M. British J of Nutrition. Antioxidant probiotic fermented milk decreases oxidative stress-mediated atherogenicity in human. 2003: 90, 2, 449-456) and total antioxidative status (TAS) was measured by commercial kit (TAS, Randox Laboratories Ltd., UK).
-
TABLE 2 Total antioxidative activity (TAA) and total antioxidative status (TAS) of Lactobacillus plantarum Inducia DSM 21379 Strain TAA (%) TAS (mmol/l) L. plantarum Inducia DSM 21379 26 ± 1.2 0.13 ± 0.04 L. plantarum DSM 21380 22 ± 5 0.05 ± 0.02 Production of nitrogen mono-oxide (NO) - Method. Nitrogen mono-oxide production measurements were carried out with 24 h old intact cells in 500μ of MRS broth with Apollo 4000 free radical analyzer (WPI, Berlin, Germany) and electrodes of type. ISO-NOP electrode signals were registered during 5-7 minutes. Mean signal strength was calculated. Each experimental point was measured in 4 independent parallels and each parallel was measured twice. NO concentration was calculated according to the standard curves correlation with the strength of the electrodes signal.
-
TABLE 3 NO concentration (μM) produced by Lactobacillus plantarum DSM 21379 Strain number NO concentrations (μM) L. plantarum DSM 21379 2.7 ± 1.2 L. plantarum DSM 21380 2.6 ± 0.8 L. coprophilus 2.1 ± 1.1 L. plantarum 2.1 ± 0.9 L. paracasei ssp paracasei strain no 1 1.3 ± 0.8 L. paracasei ssp paracasei strain no 2 1.8 ± 0.9 L. paracasei ssp paracasei strain no 3 2.8 ± 1.6 L. buchneri 2.0 ± 1.1 In vitro polyamines production of Lactobacillus plantarum Inducia DSM 21379 - Method. Microbial strains were suspended in physiological saline according to McFarlandi turbidity standard (109 CFU/ml) and 0.5 ml of each strain suspension was seeded into decarboxylation medium (a 4.5 ml) and incubated at 37° C. for 4 days (Bover-Cid and Holzapfel W. H. Improved screening procedure for biogenic amine production by lactic acid bacteria. Int J food Microbiol 1999; 53, (1); 33-41(9)).
- For detection of BA 200 μl of medium was derivatized for GC analyze by modified method of Nakovich (Nakovich, L. Analysis of biogenic amines by GC/FID and GC/MS. Thesis, Virginia polytechnic institute, USA. 2003).
- GC analysis were carried out by gas chromatograph HP 6890 Series GC System, with capillary colonna HP-5 19091J-413 (30 m×0.32 mm; 0.25 μm) with 160° C. 1 min, 20° C./min 280° C. 15 min; and detector (FID) 300° C.
-
TABLE 4 Production of polyamines in vitro in the decarboxylation medium (Arena, M. E. and Manca de Nadra, M. C. Biogenic amine production by Lactobacillus. J Appl Microbiol, 2001; 90; 158-162) Polyamines (μg/ml) and biogenic amines Arginine Glutamine Lysine Ornithine Histi-dine Putres- Cadav- Putres- Cadav- Putres- Cadav- Putres- Cadav- Cadav- Sample cine erine cine erine cine erine cine erine erine L. plantarum 0 0.4 1.2 0.5 0 0.4 1.9 0 0 Inducia DSM 21379 L. plantarum 0 0 0 0 0 0.3 0.5 0.6 0 DSM 2137980 - Lactobacillus plantarum strain Inducia DSM 21379 is able to produce cadaverine from arginine, putrescine both from glutamine as well as from ornithine. But the control strain was able to produce putrescine in low amounts only from ornithine (
FIG. 1 ). Traces of cadaverine were detected both in control strain as well as in Lactobacillus plantarum Inducia DSM 21379. No histamine production was detected (Table 4). -
FIG. 1 . Production of polyamines by L. plantarum DSM 21379 in vitro in the decarboxylation medium (Arena, M. E. and Manca de Nadra, M. C. Biogenic amine production by Lactobacillus. J Appl Microbiol, 2001; 90; 158-162) (a) from ornithine (b) from glutamine. -
FIG. 2 a, 2 b, 2 c. Lactobacillus species by Pearson UPMAG cluster analyses in L. plantarum Inducia DSM 21379 group. - Subjects no 3, 6, 9, 11, 14, 15, 19, 20, 22, 23, 24 and 25.
- Four samples: at the recruitment (1), after consumption of probiotic cheese (2), after wash-out period (3) and after consumption of control cheese (4).
-
FIG. 3 . The pH values of in L. plantarum Inducia DSM 21379 in xylitol containing and control modified MRS media in microaerobic and anaerobic environment. -
FIG. 4 . Presence of toxA and B genes in C. difficile VPI 10643 by reverse transcription (RT) and real-time PCR amplification (qPCR). -
FIG. 5 . Presence of toxB gene in liver and small intestine of a hamster treated with ampicillin and C. difficile by reverse transcription (RT) and real-time PCR amplification (qPCR). -
FIG. 6 . a) Normal mucosa of large intestine after probiotic administration and b) mucosa with C. difficile infection. -
FIG. 7 . Morphological changes in experimental CDAD infection. Moderate hyperaemia in a) small intestine and b) large intestine and intense hyperaemia in c) pancreas and d) spleen. Pseudomembrane in e) small intestine and PMN infiltration with pseudomembrane f) in large intestine. - Test with Estonia Cheese
- Method. Microorganism Lactobacillus plantarum Inducia DSM 21379 was added to the cheese milk of Dairy Cooperative E-Piim, (inoculation dose 3×108 CFU/vat) and the milk was renneted (25 min). The curds were cut (25 min), heated (34° C. 15 min), dried (25 min), pressed, drained (1 h), salted in brine (12° C.; 20% NaCl; pH 4.7) 20 h, drained and dried (8 h), backed into plastic and ripened at 12° C. for at least 4 weeks.
-
TABLE 5 Dynamics of microflora in Lactobacillus plantarum Inducia DSM 21379 comprising cheese. L. plantarum Inducia DSM Control 21379 comprising cheese cheese Sample Day 14 Day 21 Day 30Day 14Day 21 Day 30total counts 8 × 108 4 × 108 1010 2 × 108 3 × 108 2 × 108 Lactobacillus 5 × 108 2 × 108 1010 105 — 3 × 103 sp L. plantarum 5 × 108 2 × 108 1010 — — 3 × 103 cocci 3 × 108 2 × 108 109 2 × 108 3 × 108 108 spore-forming — — 103 — 107 108 microbes L. casei — — — 105 . —
I. Lactobacillus plantarum Inducia DSM 21379 for Enhancing Cellular Immunity - Method. Cheese samples were extracted (20
ml 50% methanol solution was added to 10 g of cheese and incubated at 45° C. for 1 h, cooled to 30° C. and centrifuged) and 200 μl of upper layer was derivatized for GC analyze by modified method of Nakovich (Nakovich, L. 2003 Analysis of biogenic amines by GC/FID and GC/MS). - GC analysis were carried out by gas chromatograph HP 6890 Series GC System, with capillary colonna HP-5 19091J-413 (30 m×0.32 mm; 0.25 μm). The column temperature program 160° C. 1 min, 20° C./min 280° C. 15 min; and detector (FID) 350° C.
- The production of putrescine and tyramine was related to that: in different lots in comparison with control-cheese putrescine content increased 3-11 times and tyramine content accordingly 2-5 times.
- Lactobacillus plantarum Inducia DSM 21379 belongs to the facultatively heterofermentative group of lactobacilli and therefore the content of tyramine in cheeses was significantly lower than that of strains of OHEL group. On the other hand, the content of putrescine was higher.
-
TABLE 6 Biogenic amines and polyamines in Lactobacillus plantarum Inducia DSM 21379 comprising test-cheeses from industrial test-trials Viable counts of strain Viable incorporated count of L. into cheese Amines (mg/kg) Planta-rum (CFU/g) at Tyra- Putre- Cadav- Tensia DSM Sample day 3-4 after mine scine erine 21379 in L. plantarum 3 × 108 4.83 20.28 0 2 × 107 Inducia DSM 21379, 1. Batch Control cheese — 2.31 1.82 0 — 1. Batch L. plantarum 3.3 × 107 13.57 24.67 0 2 × 106 Inducia DSM 21379, 2. Batch Control cheese — 2.63 6.64 0 — 2. Batch - Permitted concentration of tyramine in food e.g. in cheese is 200 mg/kg (Karovicova and Kohajdova. Biogenic amines in food. Chem pap. 2005; 59 (1); 70-79; Larque, M., Sabater-Molina, S. Zamora E. Biological significance of dietary polyamines. Nutrition 2007; 23(1): 87-95). Tyramine is considered toxic in concentrations of 1000-8000 mg/kg.
- Putrescine is considered toxic if detected in organism in concentration of 2000 mg/kg per body weight and total toxicity of polyamines is >300 mg/kg per food product (Larque, M., Sabater-Molina, S. Zamora E. Biological significance of dietary polyamines. Nutrition 2007; 23(1): 87-95).
- By consumption of 100 g Lactobacillus plantarum Inducia DSM 21379 comprising cheese the subject gets ca 3 mg of putrescine. Thus, in the case of person of 70 kg the concentration is up to 50 μg per kg, which does not express toxic effect.
- In the experimental model with NIH mice 3 groups of mice consumed different cheeses during 30 days (control cheese with no additives, Lactobacillus plantarum strain Inducia DSM 21379 2×108 cfu/g comprising cheese).
- Cheese was administered to mice at night (normal awake time for mice) 4.4 g/per mouse, daily ad libitum regular commercial diet. Consumed amount of cheese was 3.5-4.2 g/per night.
- Mice stayed in good condition, no changes in fur and digestion was detected. Cheese administration caused increase of body weight: body weight at the beginning of the trial was 22.9-29.8 g and at the end of the trial a weight gain was 2-6.1 g. The mice were sacrificed by cervical dislocation at
day 30. No translocation of lactobacilli or other bacteria of the microflora to blood or organs was detected at the autopsy. -
TABLE 7 Total counts of lactobatsilli in faeces, ileum and colon Sample Control group (cheese Test group (cheese without L. plantarum comprising L. plantarum Faecal Inducia DSM 21379 Inducia DSM 21379 samples was administered) was administered) Day 06.7 7.6 Day 108.0 8.3 Day 15 7.0 8.0 ileum 3.0-7.1/5.95* 6.3-7.7/6.95* colon 4.4-7.3/6.65* 6.9-7.8/7.45* *Student t-test p = 0.001 - With seeding from ileum and colon from the mice administered with Lactobacillus plantarum Inducia DSM 21379 total counts of lactobacilli were found to be increased significantly both in ileum and colon.
- Tissue samples from the liver, spleen, ileum and colon were fixed in formalin and embedded in paraffin. Microtome-cut tissue samples were stained with hematoxyline-eosine.
- No morphological shifts were found in organs (liver and spleen), which proves the safety of Lactobacillus plantarum Inducia DSM 21379.
- In the ileum quantity and shape of intestinal mucosa, count of goblet and Paneth cells was evaluated and formation of follicles and diffuse multiple deposits by lymphocytes.
- In the colon attention was paid to the numerously goblet cells containing surface epithelium and to the characteristics of lymphatic tissue in connective tissue of mucosa.
-
TABLE 8 Patomorphological evaluation of mice organs after administration of Lactobacillus plantarum Inducia DSM 21379 comprising cheese. Mice group Liver Spleen Ileum Colon L. plantarum Hyperaemia ii Lymph Lymph Inducia 6/10* follicles follicles DSM 21379 6/10* 8/10* comprising cheese consumed animals Control cheese Hyperaemia Hyperaemia Lymph Lymph consumed animals 3/10* 1/10 follicles follicles 3/10* 4/10* *p < 0.05 - Administration of Lactobacillus plantarum Inducia DSM 21379 comprising cheese during 1 month enhanced liver hyperemia and raised significantly lymphatic follicles (immunocytes) of mice ileum and colon in comparison with control mice. These results refer to enhancement of the defense capability of intestinal mucosa and liver functions.
- The double-blind placebo-controlled (DBPC) cross-over exploratory trial (International registration number ISRCTN38739209) was conducted according to the guidelines of Declaration of Helsinki. The trial was approved by the Ethics Review Committee on Human Research of the University of Tartu, Estonia (approval number 158/10, 26.03.2007). All participants signed their written informed consent at the enrollment and were given the possibility to withdraw from the study any time.
- The clinical trial with healthy volunteers evaluated the impact of putrescine, NO and antioxidative compounds producing Lactobacillus plantarum Inducia DSM 21379 comprising food consumption on (Estonian cheese) 1) safety for the consumer; 2) humoral and cell immunity parameters of blood; 3) effect on intestinal microflora; 4) and urine metabolites, to detect possible health-promoting effects.
- The study group consisted of healthy volunteers, both male and female (M/
F 4/8) aged 20-48 years. For exclusion criteria diabetes, glucose and glycohemoglobin HbA1c from blood sera were detected. The trial was randomized double-blind cross-over study. Trial started with 3-week consumption of test cheese. Volunteers consumed the test cheese for 3 weeks. After a 2-week washout period, volunteers were crossed over to another 3 weeks of control cheese administration. - Lactobacillus plantarum Inducia DSM 21379 content in 30 old test cheeses was 6×107 cfu/g.
- Before consumption the test cheese was incubated with Lactobacillus plantarum Inducia DSM 21379 for 30 days at 12° C. Regular Estonian cheese of Edam type without Lactobacillus plantarum Inducia DSM 21379 served as a control.
- The trial was a randomized blinded cross-over placebo controlled trial. Trial started with 3-week consumption of test cheese, followed by 2 week washout period, after which the control cheese was consumed for 3 weeks. Dose 50 g/day.
- Results
- 1) Safety
- No discomfort, abdominal pain or other negative symptoms were reported by trial participants. After cheese trial with volunteers, the values of systemic inflammation markers (U-CRP, ultrasensitive CRP, and leucocytes) were not changed and were within the normal range.
- The consumption of probiotic Lactobacillus plantarum Inducia DSM 21379 cheese did not cause changes in WBC counts (leucogram) (Table 9). No change was also detected in the values of essential allergy marker IgE in comparison with pre-trial period.
- Consumption of Lactobacillus plantarum Inducia DSM 21379 comprising cheese had no negative impact on organisms' kidney and liver function nor affected according parameters (ASAT, ALAT albumine, blood sera creatinine).
- Thus in healthy subjects the consumption of Lactobacillus plantarum DSM 21379 comprising cheese does not cause systemic inflammation, allergic sensibilisation or causes harm to essential organs.
- 2) Intestinal Microflora
- Method. Microbial DNA was isolated from cheese by QIAamp DNA Mini Kit (QIAGEN) and amplified with primers Uni-515-GC-rev (ATCGTATTACCGCGGCTGCTGGCA-GC), Lab-159-f (GGAAACAGA/GTGCTAATACCG) (Heilig H G, Zoetendal E G, Vaughan E E, Marteau P, Akkermans, A D L, de Vos W M, /et al./ Molecular diversity of /Lactobacillus/ ssp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA. /Appl Envir Microbiol /2002; 68: 114-123). Subsequently, the PCR product was separated by DGGE electrophoresis in 30-60% acrylamide containing gel with Dcode™ System technique. (Bio-Rad, Hercules, Calif.). Gels were analyzed by BioNumerics 2.5 (Applied Maths, Belgium) software according to Peasoni correlation (Fromin, N.; Hamelin, J.; Tarnawski, S.; Roesti, D.; Jourdain-Miserez, K.; Forestier, N.; Teyssier-Cuvelle, S.; Gillet, F.; Aragno, M.; Rossi, P. Statistical analysis of denaturing gel electrophoresis (DGE) fingerprinting patterns Environmental Microbiology 2002; 4 (11), 634-643) (
FIG. 2 a, 2 b, 2 c). - Results
- Consumption of Lactobacillus plantarum Inducia DSM 21379 comprising cheese changed lactobacilli pattern profile in feces in 5 persons of 12. These changes remained stable in 3 persons of 5 even 2 weeks after completing the trial.
- Thus, consumption of Lactobacillus plantarum Inducia DSM 21379 comprising cheese affects the composition of human intestinal lactoflora.
- 3) Humoral and Cellular Parameters of Blood Sera
- It appeared that Lactobacillus plantarum Inducia DSM 21379 comprising cheese induces the raise of cytokine IL-6, in volunteers, which indicates the stimulation of cellular immunity. This finding was confirmed by the increase of blood monocytes at the end of the trial (p=0.015), whereas indices of blood cells were within the normal range.
- Positive correlation after completing the cheese consumption appeared between IL-6 and blood monocytes (r=0.653, p=0.029, n=11). The linear regression model confirmed the correlation (R2=0.405, R2 adj=0.338, =0.035)
- Enhancement of parameters of cellular immunity is in accordance with results on animal model described above; where the administration of Lactobacillus plantarum Inducia DSM 21379 induced significantly Peyer's patches i.e. lymph follicles in the intestine. In these follicles interaction of the components of the immune system occurs. Proinflammatory cytokines incl. induction of IL-6 play important role in activation of TH1 type lymphocytes against bacteria through which macrophages i.e. blood monocytes are retroactive activated. Thereupon blood monocytes produce also IL-6.
- The increase of the share of cellular immunity is explainable also by the suppression of humoral response e.g. somewhat decreased production of antibodies (IgA, IgG), which however remained within the normal range.
-
TABLE 9 Immunological parameters of blood after consumption of probiotic Lactobacillus plantarum Inducia DSM 21379 comprising cheese Immunity At the End of the P Normal range parameters recruitment trial values and units Ultrasensitive 1.9 ± 1.6 3.3 ± 2.7 1.0 <5 mg/L CRP Leukocyte 6.3 ± 1.7 6.9 ± 1.6 0.116 4-10 × 109/L counts × 109 Lymphocytes 2.3 ± 0.5 2.2 ± 0.4 0.878 0.8-2.9 × 109/L Monocytes 0.55 ± 0.17 0.64 ± 0.15 0.032 0.15-0.75 × 109/L Cytokine IL-6 2.7 ± 1.0 3.8 ± 1.7 0.020 <3.4 ng/L IgA antibodies 2.5 ± 0.9 2.3 ± 0.8 0.009 0.7-4.0 g/L IgM antibodies 1.3 ± 0.5 1.3 ± 0.5 0.776 0.4-2.3 g/L IgG antibodies 12.9 ± 3.2 12.4 ± 3.0 0.017 7.0-16 g/L IgE antibodies 19.6 ± 21.2 21.4 ± 25.9 0.232 <85 kU/L - 4) The Urine Metabolites
- For the evaluation of the content biogenic amines before the consumption of the probiotic and the efficiency of the stabilization period, the morning urine and gas chromatography method were used.
- Method: urine samples were derivatized with propylchlorophormate for GC analyze by modified method of Uglandi (Ugland H G; Krough M, Rasmussen K E: Aqueous alkylchloroformate derivatization and solid-phase microextraction: determination of amphetamines in urine by capillary gas chromatography. J Chromatography B Biomed Sci Appl 1997; 701:29-38).
- GC analysis were carried out by gas chromatograph HP 6890 Series GC System (Hewlett Packard, Avondale, Pa., USA), with capillar colonne HP-5 19091J-433 (30 m×0.25 mm; 0.25 μm) The column temperature program 150° C. 1 min, 20° C./min 280° C. for 5 min; and detector (FID) 250° C. The biogenic amines concentration was calculated according to nmol/mol creatinine
-
TABLE 10 Polyamines and biogenic amines content in the morning urine (nmol/mol creatinine) of probiotic cheese consumers Control cheese (without Probiotic cheese comprising L. Lactobacillus plantarum plantarum Inducia DSM 21379 Inducia DSM 21379) BL1 PRO BL2 PL P values mean ± stdev mean ± stdev mean ± stdev mean ± stdev paired t-test range range range range BL1 vs PRO/ (median) (median) (median) (median) BL2 vs PL Put 0.064 ± 0.072 0.082 ± 0.058 0.043 ± 0.044 0.044 ± 0.060 0.432/0.432 0-0.191 0-0.191 0-0.126 0-0.216 (0.030) (0.077) (0.033) (0.031) acPut 0.606 ± 0.559 1.087 ± 1.451 0.796 ± 0.689 0.635 ± 0.291 0.021/0.850 0.151-2.104 0.307-5.049 0.068-2.167 0.154-1.219 (0.435) (0.447) (0.600) (0.594) DAP 0.079 ± 0.092 0.059 ± 0.089 0.056 ± 0.089 0.117 ± 0.142 0.411/0.195 0-0.249 0-0.216 0-0.253 0-0.418 (0.055) (0) (0) (0.055) acSpd 0.251 ± 0.227 0.384 ± 0.198 0.354 ± 0.210 0.425 ± 0.260 0.089/0.464 0-0.813 0.043-0.686 0.085-0.668 0.065-0.831 (0.232) (0.384) (0.304) (0.396) Cad 0.066 ± 0.123 0.069 ± 0.162 0.067 ± 0.093 0.044 ± 0.085 1.0/0.540 0-0.364 0-0.569 0-0.293 0-0.228 (0) (0) (0.016) (0) His 0.231 ± 0.226 0.387 ± 0.524 0.211 ± 0.364 0.478 ± 0.684 0.910/0.250 0-0.595 0-1.401 0-1.229 0-2.093 (0.156) (0.122) (0) (0.235) Tyr 0.153 ± 0.161 0.101 ± 0.132 0.093 ± 0.096 0.212 ± 0.285 0.167/0.149] 0-0.476 0-0.427 0-0.257 0-1.035 (0.102) (0.050) (0.093) (0.179) Put—putrescine, acPut—N-acetylputrescine, DAP—1.3-diaminopropane, acSpd—N 8-acetylspermidine, Cad—cadaverine; His—histamine, Tyr—tyramine - The content of polyamines (putrescine, acetylputrescine and acetylspermidine) in urine increased after consumption of L. plantarum Inducia DSM 21379 comprising probiotic cheese. A significant correlation (R=0.383 p<0.01, n=48) appeared between the contents of acetylputrescine and acetylspermidine in the urine of volunteers.
- At the same time the content of all polyamines incl. putrescine, acetylspermidine and acetylspermine as well as biogenic amines remained within the normal range in the urine.
- Lactobacillus plantarum strain Inducia DSM 21379 is able to produce putrescine in vitro as well as in cheese. Consumption of probiotic Lactobacillus plantarum Inducia DSM 21379 cheese elevated the content of acetylputrescine in urine of trial participants.
- Acetylputrescine represents a detoxified compound, elevated content of which proves putrescine production by Lactobacillus plantarum Inducia DSM 21379 in gastrointestinal tract of volunteers or absorption and metabolism of additional amounts of putrescine, consumed with cheese. On the other hand, this indicates the successful adaptational reaction of organism to deal with superfluous amounts of putrescine by excreting it with urine in acetylated form.
- The immunostimulative effect of putrescine produced by Lactobacillus plantarum Inducia DSM 21379 was confirmed by the correlation between blood cytokine IL-6 and the quantity of macrophages (monocytes), which in this case could be considered activated macrophages. The finding mentioned together with H2O2 is essential for the organisms' defense against foreign cells (microbes, cancer cells).
- Physiological doses of putrescine occurring in the gut due to Lactobacillus plantarum Inducia DSM 21379 could theoretically enhance the regeneration of the epithelium of intestinal mucosa and apoptosis of old cells, thus avoiding the hyperproliferation of epithelium. These mechanisms ensure the barrier function of intestinal mucosa and protects against penetration of allergens.
- Consumption of Lactobacillus plantarum Inducia DSM 21379 cheese regulates the amount and activity of blood monocytes through IL-6 which finding together with lymph follicles (increase of carriers of cellular immunity) demonstrated in experimental animals improves the barrier function of intestinal mucosa and supports organisms' immunological defense functions.
- The double-blind placebo-controlled (DBPC) cross-over exploratory trial (International registration number ISRCTN68198472) was conducted according to the guidelines of Declaration of Helsinki. The trial was approved by the Ethics Review Committee on Human Research of the University of Tartu, Estonia (approval number 178/T-13 19.01.2009). All participants signed their written informed consent at the enrollment and were given the possibility to withdraw from the study any time.
- The objective of the clinical trial (randomised cross-over placebo controlled double-blind clinical trial, was to assess the safety and effect on the intestinal microflora of healthy volunteers of the Lactobacillus plantarum Inducia DSM 21379 containing yoghurt.
- Subjects and Methods.
- The participants were 27 voluntary healthy persons of both sexes (M/
F 10/17, 29.2±9.3 yrs). For exclusion latent diabetes, glucose, and glycohemoglobione (HbA1c) were measured form blood serum. Test-yogurt contained Lactobacillus plantarum strain Inducia DSM 21379 (5×106-107 cfu/ml). Yoghurt without probiotic additive served as control. The trial started 3 week consumption of test-yoghurt, followed by a two-week washout period, after that the participants consumed the control yoghurt for 3 weeks. The daily dose was 108-5×109 cfu). - Serum Humoral and Cellular Immunity Parameters
- It was found that yogurt containing Lactobacillus plantarum Inducia DSM 21379 induced chemoattractant protein (MCP, p=0.016) in the serum of volunteers, referring the stimulation of humoral part of the immune system. This finding was positively correlated with the increase of IL 10 (r=0.583; p=0.009).
- The increase of the parameters of humnoral immunity was in accordance with the results obtained in the three weeks of administration of cheese comprising Lactobacillus plantarum DSM 21379 Inducia as described above.
-
TABLE 11 Content (pg/ml) of cytocines in the blood seerum of volunteers during the trial Probiotic yoghurt Control yoghurt P valus BL1 PRO BL2 PL BL1 vs PRO/BL2 vs PL INFγ 2.9 ± 4.3 3.8 ± 4.2 3.7 ± 3.6 1.9 ± 1.8 0.084/0.107 TNFα 4.6 ± 3.2 5.0 ± 2.6 4.0 ± 1.4 3.8 ± 1.2 0.225/0.376 VEGF 158.8 ± 15.8 157 ± 120.4 152.2 ± 106.8 163.0 ± 157.7 0.465/0.841 MCP 218.4 ± 98.1 251.3 ± 145.1 256.2 ± 142.2 230.8 ± 116.7 0.016/0.156 EGF 54.8 ± 57.6 53.4 ± 38.4 53.2 ± 56.5 52.0 ± 45.1 0.679/0.353 VEGF—vascular endothelial growth factor MCP—monocyte chemoattractant protein EGF—epidermal growth factor - Thus, administration of L. plantarum Inducia containing yoghurt activated the monocyte chemoattractant protein, which demonstrates the increased immune activity.
- After the administration of Lactobacillus plantarum Inducia containing yoghurt, the content of acetylated putrescine increased in the morning urine of patients.
- The content of acetylated putrescine was correlated to (r=0.439 p=0.037) the increase of the amount of spermidine in the morning urine of patients.
- These results are consistent with the results of the clinical trial of probiotic cheese. At the same time, the concentration of both polyamines incl. putrescine and acetylated putrescine as well as biogenic amines in the morning urine remained within normal limits.
-
TABLE 12 Content of polyamines and biogenic amines in the morning urine of the subjects consuming probiotic yoghurt (nmol/mol creatinine) Probiotic yoghurt Control yoghurt P values BL1 PRO BL2 PL BL1 vs PRO/BL2 vs PL Put 0.084 ± 0.170 0.032 ± 0.060 0.033 ± 0.039 0.029 ± 0.036 0.069/0.776 acPut 0.275 ± 0.231 1.015 ± 1.816 0.349 ± 0.240 0.538 ± 0.719 0.002/0.160 DAP 0 0.038 ± 0.109 0.005 ± 0.017 0.064 ± 0.200 0.181/0.059 Spd 0.168 ± 0.081 0.221 ± 0.147 0.188 ± 0.117 0.64 ± 0.269 0.218/0.377 Cad 0 0 0 ± 0.001 0.001 ± 0.005 NA/1.0 Tyr 0 0 0 NA Put—putrescine, acPut—N-acetylputrescine, DAP—1.3-diaminopropane, acSpd—N 8-acetylspermidine, Cad—cadaverine; Tyr—tyramine.
II. Use of L. plantarum Inducia DSM 21379 as Hypocholesterolemic Agent by Decreasing LDL-Cholesterol in Blood - Methods. Assessing the Bile Salt Hydrolase (BSH) activity L. plantarum Inducia DSM 21379 was performed according to Cuñé Castellana, 2009 (
EP 2 485743 B1; AB Probiotics S.A.) - Three Lactobacillus spp strains were cultured overnight on MRS agar in microaerobic conditions at 37° C. After incubation, cultures were standardised to McFarland 3.0. The single-strain cultures were assayed for BSH activity. Cultures were impregnated around the sterilized paper disks on MRS agar plates supplemented with 4% (w/v) sodium salt of taurodeoxycholic acid (TDCA, Sigma, USA) and 0.37 g/1 CaCl2. Plates were anaerobically incubated at 37° C. for 72 h, and the diameter of the precipitation zones around the disks were measured. BSH activity was then calculated by subtracting the disc diameter (DD, mm) from the inhibition zone diameter (IZD, mm) and dividing this difference by two following the formula BSH activity=(IZD-DD)/2 (Table 13).
-
TABLE 13 Bile salt hydrolase (BSH) activity of L. plantarum Inducia DSM 21379 BSH activity (mm) L. plantarum Inducia DSM 21379 1.7 L. plantarum BAA 793 1.5 L. gasseri DSM 23882 0.75 - BSH activity of L. plantarum Inducia DSM 21379 was higher than reference L. plantarum strain BAA793 and L. gasseri DSM 23882 (Table 13).
- The purpose of the human intervention trial ISRCTN79645828 “Effect of probiotic yoghurt on blood indices and intestinal microflora of healthy volunteers” was to assess the short term (3 weeks) LDL-cholesterol decreasing ability of L. plantarum Inducia DSM 21379 in volunteers blood when consumed with yoghurt comprising said strain.
- Yoghurt preparation. The probiotic yoghurt was developed from adjusted and pasteurized (+92 . . . +95° C. 5 min) cow milk using L. plantarum Inducia DSM 21379 (2×1011 cfu/g) as an adjunct starter (inoculation dose 1 g/t). Shortly, the pasteurized milk was cooled to +35 . . . +43° C. before mixing with starter cultures and the probiotic strain. The milk was fermented until a pH 4.2 . . . 4.5 was reached and cooled to +23 . . . +27° C. The yoghurt was sweetened with 5% of sugar, packaged in plastic cups and cooled to +2 . . . +6° C. A yoghurt without probiotic adjunct served as a control.
- Design of human volunteer trial. The double-blind placebo-controlled.
- (DBPC) cross-over exploratory trial was conducted according to the guidelines of Declaration of Helsinki. The trial was approved by the Ethics Review Committee on Human Research of the University of Tartu, Estonia (approval number 190T-11, 2010). All participants signed their written informed consent at the enrollment and were given the possibility to withdraw from the study any time. The study was performed to investigate the effect of yoghurt comprising L. plantarum Inducia DSM 21379 on health biomarkers in healthy adults (n=49). Within one month prior to study participants were asked to continue their normal diet, and to avoid probiotic products (e.g. food supplements, yoghurts, cheese, kefir etc).
- Two groups of participants started simultaneously with 3-week consumption of 150 g daily of test-yoghurt i.e. yoghurt comprising L. plantarum Inducia DSM 21379 (4×107 cfu/g) or control yoghurt. The daily dose of the probiotic L. plantarum Inducia was 6×109 cfu. After a two-week washout period, the volunteers were crossed over to another three weeks period of consumption of the probiotic yoghurt or control yoghurt.
- Clinical Investigations
- The subjects were clinically investigated and blood plasma samples were collected after an overnight fast and abstinence from any medications, tobacco, alcohol and tea or coffee. Each participant was evaluated for anthropometrical indices. Body mass index (BMI) was calculated as the weight (kg) divided by squared height (m2). BMI was used to classify normal weight range (18.5-24.9 kg/m2), overweight (≧25.0 kg/m2) and obesity (≧30.0 kg/m2) in healthy volunteers (WHO. The International Task Force. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation on Obesity. Geneva, Switzerland. WHO/Nut/NCD/98. 1998; 1).
- The samples of fasting blood were collected four times: at recruitment, after administration of either the L. plantarum Inducia DSM 21379 comprising product or control product, after wash-out period, and after the administration of the control or probiotic product at the end of the trial.
- Haematological indices: plasma lipids: total cholesterol, LDL-cholesterol (LDL), HDL-cholesterol (HDL) and triglycerides were determined by standard laboratory methods using certified assays in the local clinical laboratory (United Laboratories of Tartu University Clinics, Estonia). Intervals for routine laboratory tests proposed by Nordic Reference Interval Project (NORIP, Rustard P., Felding P., Franszon L., Kairisto V., Lahti A., Martensson A., Hyltoft Petersen P., Simonsson P., Steensland H., Uldall A. (2004) The Nordic Reference Interval Project 2000: recommended reference intervals for 25 common biochemical properties. Scand J Clin Lab Invest 64: 271-284) were used as reference.
- Change in oxidized LDL (oxLDL, pmol/L) was measured by using the enzyme-linked immunosorbent assay (ELISA) kit (Mercodia, Sweden, Cat No 10-1143-01).
- Statistical Analysis
- Statistical analysis was performed by using R 2.10.1 (http://www.r-project.org Retrieved 25.03.2014) and GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, Calif.). All data were expressed as mean and standard deviation (means±SD). Baseline and intervention data were compared by paired t-test or Wilcoxon rank sum test according to the distribution of data.
- Differences were considered statistically significant if the value was p<0.05.
- The two groups of healthy volunteers of the cross-over trial did not differ in their clinical data (Table 14).
-
TABLE 14 Baseline values of healthy volunteers Group 1 n = 25 Group 2 n = 24 P value Age 35.8 ± 12.0 38.0 ± 12.7 0.617 19.0-58.0 19.0-62.0 (34.0) (36.5) Sex F/M) § 18/7 18/6 1.0 HbA1c * 5.5 ± 0.2 5.5 ± 0.3 0.976 BMI 23.8 ± 4.3 25.2 ± 5.2 0.297 18.1-34.6 18.6-43.4 (22.7) (25.3) Waist//hip 0.78 ± 0.06 0.79 ± 0.07 0.434 0.68-0.97 0.68-0.94 (0.77) (0.79) Systolic blood 118.3 ± 10 121.6 ± 15.5 0.660 pressure 101.0-144.5 98.5-158.0 (118.0) (117.8) Diastolic blood 77.5 ± 7.4 78.6 ± 8.8 0.719 pressure 63.5-92.5 65.5-98.5 (76.7) (79.3) Cholesterol 5.1 ± 1.1 5.2 ± 0.9 0.952 LDL-cholesterol 3.4 ± 1.0 3.4 ± 1.2 0.873 HDL-cholesterol 1.7 ± 0.4 1.7 ± 0.5 0.719 Triglycerides 1.2 ± 1.0 1.1 ± 0.3 0.298 Glucose 4.9 ± 0.5 4.9 ± 0.4 0.560 * glucohaemoglobin, § Fisher exact test -
TABLE 15 Metabolic indices of blood sera during the trial P values *BL1 vs PRO/ Probiotic yoghurt Control yoghurt BL2 vs PL Probiotic Placebo (BL1 vs BL2, Baseline 1 period Baseline 2 period PRO vs PL) Cholesterol 5.2 ± 1.0 5.1 ± 0.9 5.1 ± 0.9 5.1 ± 0.9 0.081/1.0 total 3.0-8.1 3.2-7.1 3.2-7.5 3.5-7.7 (0.588, 0.172) (5.1) (5.0) (4.9) (5.0) LDL- 3.3 ± 1.0 3.0 ± 0.9 3.3 ± 1.1 3.1 ± 1.0 <0.001/0.099 cholesterol 1.3-6.2 1.2-5.0 1.1-6.1 0.9-5.6 (0.358, 0.329) total (3.3) (2.9) (3.2) (2.9) HDL- 1.7 ± 0.5 1.7 ± 0.5 1.7 ± 0.5 1.7 ± 0.5 0.569/0.402 cholesterol 0.8-3.1 1.0-3.3 0.9-3.0 0.9-3.1 (0.896, 0.788) total (1.8) (1.7) (1.8) (1.7) Triglycerides 1.1 ± 0.8 1.1 ± 0.6 1.1 ± 0.6 1.1 ± 0.6 0.694/0.456 total 0.4-4.4 0.3-3.9 0.5-4.0 0.5-4.1 (0.834, 0.412) (0.9) (0.9) (1.0) (1.0) *BL1: baseline 1; PRO: probiotic period, BL2: baseline 2; PL: placebo period - Change in oxidized LDL (oxLDL, pmol/L) value during the trial: at the start 52.7±16.2 49.0±15.3 vs at the end of the 3-week probiotic treatment, p=0.001)
- The main changes after L. plantarum Inducia DSM 21379 consumption were revealed in the content of LDL-cholesterol particles. The LDL-cholesterol content was decreased after consumption of L. plantarum Inducia DSM 21379 comprising yoghurt (Table 15).
- Thus, the consumption of L. plantarum Inducia DSM 21379 yoghurt during 3 weeks reduced the LDL-cholesterol level for 9.1% and the oxidized LDL level for 7% in blood.
- III. Use of L. plantarum Inducia DSM 21379 as antimicrobial agent by preventing germination of spores of C. difficile
- The purpose of the study was to assess the antagonistic activity of L. plantarum Inducia DSM 21379 against C difficile reference strains in anaerobic environment.
- Methods. The tested strains were: L. plantarum Inducia DSM 21379 and C. difficile VPI 10463 (ATCC 43255), M 13042 hypervirulent strain.
- Strains were seeded on solid media and incubated in an anaerobic environment. The suspension of bacteria in PBS was adjusted according to MacFarlandi standard (3 for 108 cfu/ml). Suspension (0.2 ml) in the 200 ml BHI media was inoculated for reaching the
concentration 105 cfu/ml. - On different timescale the bacteriological seedings for growth were performed (0.1 ml) to MRS and LAB160 media. The plates were incubated in anaerobic and microaerobic conditions. The growth was checked after 2-5 days and the results were expressed as log10 CFU/ml.
-
TABLE 16 Inhibition of growth of C. difficile reference strains after co-cultivation with L. plantarum Inducia DSM 21379 in BHI media after 0, 24, and 48 h Growth (log CFU/ml) 0 h 24 h 48 h Growth of strains as single in BHI L. plantarum Inducia 5.3 8.0 6.3 C. difficile VPI 10463 reference strain 5.8 4.6 7.5 M 13042 clinical reference strain 5.3 5.3 7.5 Growth of L. plantarum Inducia and C. difficile strains after co-cultivation in BHI L. plantarum Inducia with C. difficile VPI 5.8 8.8 7.3 L. plantarum Inducia with M reference strain 5.6 8.5 6.0 C. difficile VPI10463 strain with L. plantarum 5.5 0 0 Inducia C. difficile M 13042 strain with L. plantarum 5.3 0 0 Inducia - Complete suppression of C. difficile vegetative cells by L. plantarum Inducia DSM 21379 was discovered after co-cultivation in BHI medium further seeded on selective MRS and CD LAB180 media after 48 h incubation L. plantarum Inducia DSM 21379 showed the highest values at 24 h in the BHI medium. After 48 h the growth yield of L. plantarum Inducia DSM 21379 was modestly suppressed equally in single culture (6.3 log cfu/g) or if combined with C. difficile strains (7.3 and 6.0 log cfu/g).
- The purpose of the following in vitro experiment was to determine the antimicrobial effect of L. plantarum Inducia DSM 21379 vegetative cells of on reference and clinical C. difficile strains. The distinction between the suppressive effect of natural (acidic) and neutralised supernatant (inhibitory substances e.g. peptides) of L. plantarum Inducia DSM 21379 helps to discriminate between two mechanisms—either impact of organic acids or presence of bacteriocins.
- Material (Strains) (Table 17)
- L. plantarum Inducia DSM 21379
- Clostridium difficile Reference Strains VPI 10463 and M 13042
- Clostridium difficile Clinical Strains (11 Strains)
- Methods. Antimicrobial activity of L. plantarum Inducia DSM 21379 supernatant was determined against reference and clinical C. difficile strains by a microtitre plate (MTP) assay.
- The L. plantarum Inducia DSM 21379 was maintained at −80° C. in microtubes on glass-beads and was activated trice in MRS broth with 0.15% agar, incubated under microaerobic conditions (10% CO2) at 37° C. for 24 h. Overnight L. plantarum Inducia DSM 21379 culture was used to inoculate BHI broth 1% v/v and was incubated in microaerobic conditions for 24 h. For detection of antimicrobial activity of L. plantarum Inducia DSM 21379, the extracellular cell free supernatant (CFS) was collected by centrifugation from a 24 h old BHI broth cultures. The pH of cell free supernatant was measured and divided in half. The on half was left acidic and the other half was neutralized with 6N NaOH to pH 6.0, the both supernatants were filter sterilized.
- C. difficile strains were maintained at −80° C. in microtubes on glass-beads and were activated trice on Fastidious Anaerobe Agar (FAA) with horse blood supplement for 24 h in anaerobic milieu (Anaerobic glove box,
gases 90% N:5% CO2:5% H2). Overnight C. difficile cultures were used for the suspension with density according to MacFarland 3.0. For evaluating the antimicrobial activity of L.plantarum Inducia DSM 21379, 20 μl of C. difficile cell suspension was added to 180 μl: (1) BHI broth (as control), (2) cell free BHI supernatant, (3) cell free neutralized BHI supernatant, (4) diluted cell free supernatant (1:1 in sterile BHI broth) and (5) diluted neutralized cell free supernatant (1:1 in sterile BHI broth). - Growth of C. difficile (change in optical density values) was measured after 48 h at OD620nm using an MTP reader and the growth rates were calculated.
- The suppressive activity of L. plantarum Inducia DSM 21379 was tested with Kruskal-Wallis test, where the growth density (OD620nm) of C. difficile control was compared with the data of C. difficile growth density in natural and neutralised and in supernatants dilutions. The statistical analysis of data was performed using PAST Statistics Web provided program.
-
TABLE 17 Antimicrobial activity L. plantarum Inducia DSM 21379 supernatant neutral (acidic) and neutralised cell free supernatant and supernatant dilution against clinical and reference strains of C. difficile after 48 h of cultivation. The density of The density of C. difficile in C. difficile in L. plantarum L. plantarum Inducia supernatant The density Inducia dilution 1:1 of C. supernatant (supernatant:BHI) difficile (natural or (natural or C. difficile in BHI neutralized) neutralized) strains (control) natural neutralized natural neutralized CDE 0.259 0.023 0.150 0.113 0.395 CDP1 0.478 0.007 0.305 −0.007 0.294 CDP2 0.510 0.001 0.550 0.193 0.651 CDP3 0.493 0.009 0.363 0.114 0.334 CDP4 0.386 0.004 0.247 0.084 0.343 CDP5 0.311 0.003 0.192 0.097 0.369 CDP6 0.503 0.003 0.208 0.107 0.264 CDP7 0.402 0.091 0.315 0.126 0.325 CDP8 0.110 0.002 0.170 0.019 0.316 CDP9 0.090 0.032 0.170 0.103 0.334 CDP10 0.209 0.023 0.050 0.093 0.331 VPI 10643 0.420 0.044 0.076 0.329 0.290 M 13042 0.402 0.005 0.249 0.083 0.304 Mean ± SD 0.352 ± 0.019 ± 0.234 ± 0.112 ± 0.350 ± 0.15a;b;c 0.03a;d;e;f 0.13b;d 0.08c;e 0.10f ap < 0.0001; bp < 0.05; cp < 0.01, dp < 0.001; ep < 0.01; fp < 0.001 - Legend: vegetative cells of clinical strains: C. difficile CDE, CDP 1-9; reference strains: C. difficile VPI 10463 (ATCC 43255) and C. difficile M13042 (epidemic strain from Canada belonging to ribotype 027).
- Thus, the strain L. plantarum Inducia DSM 21379 possess antimicrobial activity against C. difficile relying both on acid production in natural product (pH lowering) and in a smaller extent also on some antimicrobial protein-like substance still active after neutralisation of the supernatant (neutralized product) (Table 17).
- The purpose of the study was to find if xylitol influences the antagonistic activity of L. plantarum Inducia DSM 21379 against C. difficile.
- Inducia (105 cfu/ml) was incubated in MRS media where glucose was substituted for 5% xylitol or used without sugar in microaerobic and anaerobic environment. The count of lactobacilli was registered as cfu/ml of media. We tested at 2, 6, 24, and 48 h if L. plantarum Inducia DSM 21379 uses xylitol for growth in vitro in microaerobic and anaerobic conditions.
- At 24 h there was no difference in growth of L. plantarum Inducia DSM 21379 using media provided with xylitol or without it, at 24 h the growth in 5% of xylitole media was the best in microaerobic environment but a 2 log lower in anaerobic environment than that with glucose (Table 6).
-
TABLE 18 Counts of L. plantarum Inducia DSM 21379 (log cfu/ml) after growth in anaerobic and microaerobic conditions in modified MRS medium with 5% of xylitol or glucose Sugar The count of L. plantarum (log cfu/ml) Growth in the after different time of incubation conditions medium 0 2 h 6 h 24 h 48 h Microaerobic xylitol 5.6 5.60 6.24 8.0 7.2 glucose 5.41 5.48 6.94 8.8 9.0 Anaerobic xylitol 5.6 5.70 6.00 7.4 7.15 glucose 5.41 5.70 6.96 9.1 9.1 - This experiment proved that L. plantarum Inducia DSM 21379 did not effectively metabolise xylitol in MRS media. The change of pH after growth of L. plantarum Inducia DSM 21379 in 5% xylitol containing modified MRS media was tested.
- The lowest pH values by production of organic acids were seen in control media with glucose incubated in anaerobic environment. In xylitol containing media still a pH drop from pH 6.2 to pH 5.0 was seen both in microaerobic and anaerobic conditions, still substantially different from pH of control media with glucose from pH 7.5 to pH=3.2 (
FIG. 3 ). - Use of Xylitol in Metabolism of L. plantarum Inducia DSM 21379
- The purpose of the study was to measure the use of xylitol by L. plantarum Inducia DSM 21379 in microaerobic and anaerobic environments.
- Methods: Double experiments were performed by cultivation of L. plantarum Inducia DSM 21379 in in MRS medium with 5% xylitol in microaerobic and anaerobic environments for 2 to 120 h. Xylitol was detected with mass spectrometry QTRAP 3200 (Applied Biosystems, USA). The samples were centrifuged 3 min 10000 g, diluted 100 folds and 50 μl was mixed with 50 μl internal standard (5 mM D4-succinic acid in acetonitrile, 50 μl). 5 μl of dilutions were injected into mass spectrometry using 50% acetonitril/water eluent. The substrates were identified by multiple reaction monitoring (MRM) ionpairs 151/101 (xylitol) and 121/77 (internal standard). Concentration was calculated from a calibration curve made from solutions with known concentrations of commercial xylitol (Sigma-Aldrich, Germany).
- In the repeated experiments Inducia used xylitol in very low amounts as the content of the sugar was sustained at Basal value ±up to 0-0.6 mM of change (Table 19).
-
TABLE 19 Xylitol content (mM) after cultivation of L. plantarum Inducia DSM 21379 in 5% xylitol media microaerobically and anaerobically during 120 h Re- peated Xylitol 1 (mM) tests 0 h 2 h 6 h 24 h 48 h 120 h 5% xylitol I 3.1 ND 3.2 2.5 3.2 ND microaerobic II 3.4 3.4 3.3 3.2 3.3 3.3 5% xylitol I 3.1 ND 2.8 3.2 2.5 ND anaerobic II 3.4 3.4 3.2 3.2 3.3 3.5 ND—not determined - Thus, we confirmed by mass spectrometry that L. plantarum Inducia metabolises xylitol in very low amounts.
- Growth of C difficile Reference Strains in Environment Containing Xylitol and Ampicillin
- The purpose of the study was to mimic in vitro the gut environment similar to elaborated C. difficile infection model in Syrian hamsters.
- In vitro the impact of xylitol and ampicillin on growth of L. plantarum Inducia DSM 21379 and reference strains of C. difficile (VPI 10463 and the hypertoxic Ribotype 027 strain M13042) in Brain Heart medium (BHI) was tested.
-
TABLE 20 Impact of different concentrations of xylitol (0.1-5%) and ampicillin (0.75 μl/ml) on 48 h growth of Clostridium difficile and L. plantarum Inducia DSM 21379 as single in anaerobic milieu and BHI medium L. plantarum C. difficile C.difficile M strain Experimental Inducia log cfu/g VPI log cfu/g log cfu/g modulators 0 h 48 h 0 h 48 0 h 48 h BHI control 5.9 9.8 5.3 7.2 4.9 7.1 0.1% xylitol 5.3 8.0 4.7 6.4 5.0 6.9 1% xylitol 5.0 8.0 5.5 7.3 4.8 6.7 2.5% xylitol 5.5 8.3 5.0 6.7 5.0 6.0 5% xylitol 5.5 7.8 5.0 7.1 5.0 6.7 Ampicillin 5.3 7.1 5.8 7.0 4.7 7.0 0.75 μl/ml - The L. plantarum Inducia DSM 21379 and the two reference strains of C. difficile increased the number of CFU nearly for 2 to 4 logarithms after 48 h of cultivation in the control media of BHI. No changes were seen after influencing C. difficile strains with xylitol and ampicillin (Table 20).
- Growth of strain L. plantarum Inducia DSM 21379 was suppressed for ˜2 logarithms both under 5% of xylitol and 0.75 μl/ml of ampicillin. Thus, in gut microenvironment with administered antibiotic ampicillin and up to 5% xylitole the survival of L. plantarum Inducia is granted.
- The purpose of the study was to assess the growth of L. plantarum Inducia DSM 21379 and C. difficile reference strains by co-cultivation at different concentrations of xylitol and ampicillin.
- The BHI media supplemented with 5% xylitol and 0.75 μl/ml ampicillin were applied for co-cultivation of L. plantarum Inducia DSM 21379 and C. difficile reference strains in anaerobic environment (workstation Concept 400, UK) for 24 and 48 h.
- The viability of L. plantarum Inducia DSM 21379, C. difficile VPI and M reference strains after cocultivation were tested as single in BHI media with ampicillin and
xylitol 5% (1, 2a, 2b). After ten-fold serial dilutions for determining the count of L. plantarum Inducia in MRS broth was cultivated in CO2 environment and for C. difficile on LAB 160 media in anaerobic milieu. -
TABLE 21 Inhibition of C. difficile reference strains with growth of L. plantarum Inducia DSM 21379 after co-cultivation in BHI with 5% xylitol and 0.75 μl/ml ampicillin after 0, 24, 48 h in anaerobic environment Growth (log, CFU/ml) Strains/co-cultivation 0 h 24 h 48 h 1. L. plantarum Inducia 5.7 8.5 7.3 2. a. C. difficile VPI 5.0 7.7 7.2 2. b. C. difficile M reference strain 5.0 7.3 7.3 3. L. plantarum Inducia C. difficile VPI 6.0 8.3 7.0 M reference strain 5.5 8.5 8.0 4. C. difficile VPI L. plantarum 5.0 0 0 5. M reference strain Inducia 5.0 5.0 2.0 - During in vitro co-cultivation of L. plantarum Inducia DSM 21379 (3) and reference strains of C. difficile (4, 5) in the BHI medium with xylitol and ampicillin (mimicking the hamster model) the growth of vegetative cells of both C. difficile strains was suppressed. Full suppression was detectable for VPI strain and substantial reduction for 5 logarithms (from 5.0 to 2.0 log cfu/ml) was detected in the case of C. difficile strain M.
- Thus, the in vitro experiments mimicking the gut environment of experimental hamster model after antibiotic treatment showed either full or high suppression of C. difficile growth with L. plantarum Inducia DSM 21379 alone (Table 5) or combined it with xylitol (Table 21).
- The purpose of the study was to assess the influence of L. plantarum Inducia DSM 21379 on Clostridium difficile reference strain VPI 10463 caused infection in the intestinal tract of C. difficile spores challenged hamsters.
- Syrian hamsters (Mesocricetus auratus) provide a well-characterized model of Clostridium difficile infection. The colonic microbiota of hamsters treated with antibiotics is disrupted and if afterwards exposed to C. difficile spores, the animals develop C. difficile associated diarrhea (CDAD) in less than 48 h with 100% of mortality. We tested if mortality of C. difficile challenged hamsters can be decreased by administration of L. plantarum Inducia DSM 21379 according to our in vitro results.
- First, we pre-feeded hamsters daily with L. plantarum Inducia DSM 21379 in the concentration of 1010 cfu/ml by gastric gavage with/without 1
ml 20% xylitol for 5 consecutive days before administration of ampicillin (30 mg/kg). The administration of L. plantarum Inducia DSM 21379 in the aforementioned concentration was continued during the whole experiment. On Day 7 the hamsters were infected with 10-30 spores of C. difficile VPI 104631. For next 5 days the health of hamsters was followed and in case of symptoms indicating CDAD: wet tail—the C. difficile A/B toxin test was performed (X/pect Remel test). The group of hamsters infected with C. difficile VPI strain served as a control group. -
TABLE 22 Survival of C. difficile challenged hamsters (n = 15) pretreated with L. plantarum Inducia DSM 21379 and/or xylitol Number of survived hamsters Toxin test % of Test after challenge with C. difficile result/number survival groups Day 1 Day 2Day 3 Day 4Day 5of animals in group on Day 5C. difficile VPI 15 6 4 2 2 2 negative/ 2/15 10463I (n = 15) 15 13% C. difficile VPI + 5 2 2 1 0 0 negative/ 0/5 Inducia (n = 5) 5 0% C. difficile VPI + 9 9 9 5 5 4 negative/ 5/9 xylitol (n = 9) 9 56% C. difficile VPI + 9 7 7 7 7 7 negative/ 7/9 xylitol + Inducia 9 78% (n = 9) - Thus, the highest survival was found in case of combining L. plantarum Inducia DSM 21379 with xylitol solution pre-feeding prior to challenge with C. difficile spores (Table 22). In this case the toxin tests were all negative in the survived hamsters (7/9), i.e. that the germination of spores C. difficile was suppressed. If xylitol alone was applied, the toxin tests of 4 out of 5 surviving animals were negative and only in one surviving animal the toxin test was positive.
- Thus, the combination of xylitol with L. plantarum Inducia DSM 21379 works through suppression of germination of spores into vegetative cells of C. difficile able of toxin producing.
- We tested if the growth of C. difficile was still present after the intervention with Inducia and xylitol and if the A and B toxins of C. difficile were found (Table 23). In survived hamsters prefeeded with combination of L. plantarum Inducia DSM 21379 and xylitol the C. difficile vegetative cells were not found 6/7 cases (only in one case the C. difficile growth was seen) in jejunum and ileum. Both the counts of anaerobes and L. plantarum Inducia substituting indigenous lactobacilli in jejunum and ileum were high showing the reconstruction and stabilisation of intestinal microbiota after administration of ampicillin, challenge with C. difficile spores and usage of the treatment with L. plantarum Inducia DSM 21379 and xylitol.
-
TABLE 23 Total counts of anaerobes, lactobacilli, L. plantarum Inducia DSM 21379 and C. difficile in jejunum and ileum of survived hamster prefeeded with xylitol and L. plantarum Inducia DSM 21379 Cd Treat- tox jejunum ileum ment Hamster A/B ( CFU log 10/g)( CFU log 10/g)groups ID test AN LB Inducia C.d AN LB Inducia C.d C. T2-1 Neg 6.48 0 4.00 0.00 7.48 0 6.70 0.00 difficile T2-2 Neg 5.20 0 4.30 0.00 7.04 0 7.00 0.00 VPI + T2-3 Neg 7.48 0 4.30 0.00 7.30 0 6.70 0.00 xylitol + T2-4 Neg 8.70 0 6.00 5.00 8.11 0 7.60 7.00 Inducia T2-5 Neg 4.48 0 0.00 0.00 7.30 0 6.00 0.00 (n = 7) T2-7 Neg 7.18 7.08 5.00 0.00 8.11 8.08 6.78 0.00 T2-8 Neg 8.34 6.70 6.00 0.00 8.43 7.65 6.00 0.00 C. Xyl-1 Neg 5.30 3.00 ND 2.00 8.43 6.30 ND 0.00 difficile Xyl-2 Neg 7.11 5.54 ND 0.00 8.30 5.00 ND 0.00 VPI + Xyl-3 Pos 7.60 4.00 ND 5.00 8.38 5.00 ND 7.60 xylitol 24-1 Neg 7.35 7.6 ND 0 7.0 7.78 ND 0 (n = 5) 24-2 Neg 7.15 7.0 ND 0 7.8 7.78 ND 0 Pre- feeded AN—anaerobes, LB—lactobacilli; C.d—Clostridium difficile - The survival rate of hamsters was 22% higher due to L. plantarum Inducia DSM 21379 (Table 22). This was proved also by absence of toxin from intestinal content of large intestine (Table 23).
- The growth of L. plantarum Inducia was high in jejunum (range 0-6.0, median 4.0
CFU log 10/g and in ileum 6.0-7.6, median 6.7). L. plantarum Inducia DSM 21379 acted seemingly via its acid production through its SCFAs profile. - Morphological Evaluation of the C. difficile Infected Hamsters
- The typical CDAD infection was modelled in hamster model as in C. difficile infection the toxin damage of organs is the leading pathogenetic modulator.
- In our study the C. difficile VPI 10643 strain possessed both toxins A and B, and these were also present in liver and small intestine (
FIGS. 4 and 5 ). - In hamsters surviving the C. difficile infection and examined during autopsy no extensive damage of mucosa, no pseudomembranes and severe infiltration with polymorphonuclear cells was seen (
FIG. 6 a). - Some hours before death the characteristic morphological finding of damaged with C. difficile infection hamsters was the inflammation with polymorphonuclear infiltration in mucosa and presence of pseudomembranes.
- The severe enterocolitis developed the infiltration with red blood cells and polymorphonuclear leukocytes into gut mucosa, liver and spleen resulted in death of animals. In organs the hyperemia was present (
FIG. 7 a-f).
Claims (18)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/244,284 US20140335066A1 (en) | 2008-05-13 | 2014-04-03 | Lactobacillus plantarum inducia dsm 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against clostridium difficile |
PCT/EE2014/000007 WO2015149818A1 (en) | 2014-04-03 | 2014-10-31 | Lactobacillus plantarum inducia strain dsm 21379 as hypocholesterolemic agent and antimicrobial agent against clostridium difficile |
JP2016560760A JP2017515799A (en) | 2014-04-03 | 2014-10-31 | Lactobacillus plantarum Inducia strain DSM 21379 as an antimicrobial agent against cholesterol lowering agents and Clostridium difficile |
DK14799963.5T DK3193895T3 (en) | 2008-05-13 | 2014-10-31 | LACTOBACILLUS PLANTARUM STEM INDUCIA DSM 21379 AS A HYPOCHOLESTEROLEMIC AND ANTIMICROBIAL AGENT FOR CLOSTRIDIUM DIFFICILE |
EEP201800005A EE05809B1 (en) | 2008-05-13 | 2014-10-31 | Composition comrising probiotic microorganism strain Lactobacillus plantarum Inducia DSM 21379 for use in reducing risk of Clostridium difficile associated diarrhoea (CDAD) |
LTEP14799963.5T LT3193895T (en) | 2008-05-13 | 2014-10-31 | Lactobacillus plantarum inducia strain dsm 21379 as hypocholesterolemic agent and antimicrobial agent against clostridium difficile |
EP14799963.5A EP3193895B1 (en) | 2008-05-13 | 2014-10-31 | Lactobacillus plantarum inducia strain dsm 21379 as hypocholesterolemic agent and antimicrobial agent against clostridium difficile |
EEP201400038A EE05799B1 (en) | 2014-04-03 | 2014-10-31 | Composition comprising hypocholesterolemic probiotic microorganism strain Lactobacillus plantarum Inducia DSM 21379 for use in preventing cardiovascular disorders |
US15/132,286 US10272122B2 (en) | 2008-05-13 | 2016-04-19 | Lactobacillus plantarum inducia DSM 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against Clostridium difficile |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EEP200800027A EE05341B1 (en) | 2008-05-13 | 2008-05-13 | Isolated microorganism or Lactobacillus plantarum Inducia DSM 21379 as a probiotic that enhances the natural defenses of the organism, the food and the composition containing them, and the use of the microorganism in the preparation of a cell-mediated immunity |
EEP200800027 | 2008-05-13 | ||
US12/992,862 US20110274789A1 (en) | 2008-05-13 | 2009-05-12 | Isolated lactobacillus plantarum strain inducia dsm 21379 as probiotic that enhances natural immunity and food products and medicinal preparations comprising it |
PCT/EE2009/000006 WO2009138092A1 (en) | 2008-05-13 | 2009-05-12 | Isolated lactobacillus plantarum strain inducia dsm 21379 as probiotic that enhances natural immunity and food products and medicinal preparations comprising it |
US14/244,284 US20140335066A1 (en) | 2008-05-13 | 2014-04-03 | Lactobacillus plantarum inducia dsm 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against clostridium difficile |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/992,862 Continuation-In-Part US20110274789A1 (en) | 2008-05-13 | 2009-05-12 | Isolated lactobacillus plantarum strain inducia dsm 21379 as probiotic that enhances natural immunity and food products and medicinal preparations comprising it |
PCT/EE2009/000006 Continuation-In-Part WO2009138092A1 (en) | 2008-05-13 | 2009-05-12 | Isolated lactobacillus plantarum strain inducia dsm 21379 as probiotic that enhances natural immunity and food products and medicinal preparations comprising it |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/132,286 Division US10272122B2 (en) | 2008-05-13 | 2016-04-19 | Lactobacillus plantarum inducia DSM 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against Clostridium difficile |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140335066A1 true US20140335066A1 (en) | 2014-11-13 |
Family
ID=40957913
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/992,862 Abandoned US20110274789A1 (en) | 2008-05-13 | 2009-05-12 | Isolated lactobacillus plantarum strain inducia dsm 21379 as probiotic that enhances natural immunity and food products and medicinal preparations comprising it |
US14/244,284 Abandoned US20140335066A1 (en) | 2008-05-13 | 2014-04-03 | Lactobacillus plantarum inducia dsm 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against clostridium difficile |
US15/132,286 Active US10272122B2 (en) | 2008-05-13 | 2016-04-19 | Lactobacillus plantarum inducia DSM 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against Clostridium difficile |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/992,862 Abandoned US20110274789A1 (en) | 2008-05-13 | 2009-05-12 | Isolated lactobacillus plantarum strain inducia dsm 21379 as probiotic that enhances natural immunity and food products and medicinal preparations comprising it |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/132,286 Active US10272122B2 (en) | 2008-05-13 | 2016-04-19 | Lactobacillus plantarum inducia DSM 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against Clostridium difficile |
Country Status (10)
Country | Link |
---|---|
US (3) | US20110274789A1 (en) |
EP (2) | EP2288360B1 (en) |
KR (1) | KR101595042B1 (en) |
AT (1) | ATE536879T1 (en) |
DK (2) | DK2288360T3 (en) |
EE (2) | EE05341B1 (en) |
LT (1) | LT3193895T (en) |
PL (1) | PL2288360T3 (en) |
RU (1) | RU2486234C2 (en) |
WO (1) | WO2009138092A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016083450A3 (en) * | 2014-11-25 | 2016-07-21 | Dsm Ip Assets B.V. | Lactobillus for use as probiotic and blood cell populations used for evaluating immune response to agents, e.g. probiotics |
CN112553115A (en) * | 2020-12-23 | 2021-03-26 | 南昌大学 | Application of lactobacillus plantarum ZDY2013 in preparation of products for relieving kidney injury |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE05799B1 (en) * | 2014-04-03 | 2017-10-16 | Biocc Oü | Composition comprising hypocholesterolemic probiotic microorganism strain Lactobacillus plantarum Inducia DSM 21379 for use in preventing cardiovascular disorders |
EE05341B1 (en) * | 2008-05-13 | 2010-08-16 | O� Tervisliku Piima Biotehnoloogiate Arenduskeskus | Isolated microorganism or Lactobacillus plantarum Inducia DSM 21379 as a probiotic that enhances the natural defenses of the organism, the food and the composition containing them, and the use of the microorganism in the preparation of a cell-mediated immunity |
FR2955774A1 (en) | 2010-02-02 | 2011-08-05 | Aragan | PREPARATION FOR TREATING PONDERAL EXCES AND ASSOCIATED DISORDERS AND APPLICATIONS THEREOF |
ES2402014B1 (en) | 2011-09-07 | 2014-02-27 | Consejo Superior De Investigaciones Científicas (Csic) | PEPTIDE SECRETED BY LACTOBACILLUS PLANTARUM WITH IMMUNOMODULATORY FUNCTION |
PL2794930T3 (en) * | 2011-12-21 | 2017-03-31 | Compagnie Gervais Danone | Novel strain of lactobacillus mucosae |
WO2015081263A1 (en) | 2013-11-26 | 2015-06-04 | Central Biomedia, Inc. | Method and diet for immune enhanced donor blood |
CN106103696B (en) * | 2014-03-24 | 2020-01-17 | 大塚制药株式会社 | Novel lactobacillus paracasei strain |
RU2567149C1 (en) * | 2014-12-24 | 2015-11-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Горский государственный аграрный университет" | Lactobacillus plantarum STRAIN USED FOR OBTAINING OF FERMENTED MILK PRODUCTS AND PROBIOTIC PREPARATIONS |
KR101675035B1 (en) * | 2015-07-17 | 2016-11-22 | 주식회사 빙그레 | Probiotics comprising Lactobacillus sp., additives for animal feedstuff and animal feedstuff |
US9730969B2 (en) | 2015-11-06 | 2017-08-15 | Mead Johnson Nutrition Company | Nutritional compositions for promoting gut barrier function and ameliorating visceral pain |
KR101794772B1 (en) * | 2016-06-08 | 2017-12-01 | 강원대학교산학협력단 | Novel strains of Bacillus subtilis EE5 producing high amount of polyamine |
US10166262B2 (en) | 2017-04-20 | 2019-01-01 | Ewelina Sosnowska-Turek | Strain of bacteria and composition comprising the same |
KR102486970B1 (en) * | 2017-09-22 | 2023-01-10 | 주식회사 고바이오랩 | Lactobacillus plantarum having inhibitory effect against Clostridium difficile |
TWI740101B (en) * | 2019-02-12 | 2021-09-21 | 大江生醫股份有限公司 | Use of the reducing cholesterol probiotic strain |
SK502019A3 (en) * | 2019-05-15 | 2020-12-02 | Labas Miroslav | Method of production of milk and milk supplements with a unique composition of fatty acids, restoration of commensal, natural microbiota |
WO2021207247A1 (en) * | 2020-04-07 | 2021-10-14 | Kalin Health Llc | Spermidine-supplemented food products |
KR102363975B1 (en) * | 2020-12-11 | 2022-02-17 | 주식회사 바이오뱅크힐링 | Lactobacillus plantarum strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof |
CN113881604B (en) * | 2021-11-10 | 2023-02-28 | 深圳大学 | Lactobacillus plantarum MM89 and polysaccharide and application thereof |
CN115381005B (en) * | 2022-08-25 | 2023-09-19 | 中国农业科学院饲料研究所 | Application of Lactobacillus plantarum CICC 6240 in reducing antibiotic residues in aquatic products |
CN117417847B (en) * | 2023-08-22 | 2024-03-15 | 大理大学 | Clostridium marble and application thereof in preparation of antioxidant functional substances |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1195095A2 (en) * | 2000-10-05 | 2002-04-10 | St. Ivel Limited | Food products with antimicrobial lactic acid bacteria |
US20090011087A1 (en) * | 2006-03-03 | 2009-01-08 | Compagnie Gervais Danone | Process for the Manufacture of a Frozen Dessert and Frozen Dessert Thus Obtained |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5895758A (en) * | 1997-06-10 | 1999-04-20 | Bio-Energy Systems | Strain of lactobacillus Plantarum |
IT1298918B1 (en) * | 1998-02-20 | 2000-02-07 | Mendes Srl | USE OF ARGININE DEIMINASE BACTERIA TO INDUCE APOPTOSIS AND / OR REDUCE AN INFLAMMATORY REACTION AND PHARMACEUTICAL COMPOSITIONS |
JP2004506028A (en) * | 2000-08-11 | 2004-02-26 | ホイットロック,デイビッド アール. | Compounds containing ammonia-oxidizing bacteria that increase the productivity of nitric oxide and nitric oxide precursors and methods of using the same |
ITMI20020399A1 (en) | 2002-02-28 | 2003-08-28 | Ct Sperimentale Del Latte S P | DIETARY AND / OR PHARMACEUTICAL COMPOSITIONS FOR HUMAN AND / OR ANIMAL USE BASED ON MICROBIAL PROBIOTIC PREPARATIONS |
DE60323734D1 (en) * | 2002-03-21 | 2008-11-06 | Bifodan As | Lactobacillus strains |
RU2247148C2 (en) * | 2002-05-28 | 2005-02-27 | Пименов Евгений Васильевич | Strain of microorganism lactobacillus plantarum p4, strain of microorganism lactobacillus buchneri p0 and probiotic preparation based on thereof for correction of dysbacteriosis of different etiology in humans and animals |
WO2004076615A2 (en) * | 2003-02-27 | 2004-09-10 | Bioneer A/S | Immunomodulating probiotic compounds |
SE527555C2 (en) * | 2003-04-04 | 2006-04-11 | Probi Ab | Composition for treating cardiovascular disease, diabetes, cancer, Alzheimer's disease, has tannase-producing strains of Lactobacillus plantarum or Lactobacillus species that adhere to human intestinal mucosa in combination with tannin |
GB0513556D0 (en) * | 2005-07-01 | 2005-08-10 | Matforsk As | Product |
EE05340B1 (en) * | 2008-05-13 | 2010-08-16 | O� Tervisliku Piima Biotehnoloogiate Arenduskeskus | Lactobacillus plantarum Tensia DSM 21380 and its use as an antimicrobial and antihypertensive probiotic in the manufacture of a medicament and for the prolongation of food shelf-life and contamination of food |
EE05341B1 (en) * | 2008-05-13 | 2010-08-16 | O� Tervisliku Piima Biotehnoloogiate Arenduskeskus | Isolated microorganism or Lactobacillus plantarum Inducia DSM 21379 as a probiotic that enhances the natural defenses of the organism, the food and the composition containing them, and the use of the microorganism in the preparation of a cell-mediated immunity |
EP2311473A1 (en) * | 2009-10-09 | 2011-04-20 | AB-Biotics Producciones Industriales De Microbiotas, S.L. | Lactobacillus plantarum strains as probiotics |
-
2008
- 2008-05-13 EE EEP200800027A patent/EE05341B1/en unknown
-
2009
- 2009-05-12 US US12/992,862 patent/US20110274789A1/en not_active Abandoned
- 2009-05-12 AT AT09745475T patent/ATE536879T1/en active
- 2009-05-12 RU RU2010147343/10A patent/RU2486234C2/en active
- 2009-05-12 EP EP09745475A patent/EP2288360B1/en active Active
- 2009-05-12 PL PL09745475T patent/PL2288360T3/en unknown
- 2009-05-12 DK DK09745475.5T patent/DK2288360T3/en active
- 2009-05-12 KR KR1020107028014A patent/KR101595042B1/en active IP Right Grant
- 2009-05-12 WO PCT/EE2009/000006 patent/WO2009138092A1/en active Application Filing
-
2014
- 2014-04-03 US US14/244,284 patent/US20140335066A1/en not_active Abandoned
- 2014-10-31 EE EEP201800005A patent/EE05809B1/en unknown
- 2014-10-31 EP EP14799963.5A patent/EP3193895B1/en active Active
- 2014-10-31 DK DK14799963.5T patent/DK3193895T3/en active
- 2014-10-31 LT LTEP14799963.5T patent/LT3193895T/en unknown
-
2016
- 2016-04-19 US US15/132,286 patent/US10272122B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1195095A2 (en) * | 2000-10-05 | 2002-04-10 | St. Ivel Limited | Food products with antimicrobial lactic acid bacteria |
US20090011087A1 (en) * | 2006-03-03 | 2009-01-08 | Compagnie Gervais Danone | Process for the Manufacture of a Frozen Dessert and Frozen Dessert Thus Obtained |
Non-Patent Citations (1)
Title |
---|
Mikelsaar, M et al. Intestinal lactobacilli of Estonian and Swedish children. Microbial Ecology in Health and Disease. 2002. 14: 75-80. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016083450A3 (en) * | 2014-11-25 | 2016-07-21 | Dsm Ip Assets B.V. | Lactobillus for use as probiotic and blood cell populations used for evaluating immune response to agents, e.g. probiotics |
US10226492B2 (en) | 2014-11-25 | 2019-03-12 | Dsm Ip Assets B.V. | Probiotic and new biomarker |
CN112553115A (en) * | 2020-12-23 | 2021-03-26 | 南昌大学 | Application of lactobacillus plantarum ZDY2013 in preparation of products for relieving kidney injury |
Also Published As
Publication number | Publication date |
---|---|
RU2010147343A (en) | 2012-06-20 |
US10272122B2 (en) | 2019-04-30 |
DK2288360T3 (en) | 2012-03-19 |
EP3193895B1 (en) | 2020-04-15 |
EP2288360A1 (en) | 2011-03-02 |
EE05809B1 (en) | 2018-09-17 |
LT3193895T (en) | 2020-07-27 |
EE200800027A (en) | 2009-12-15 |
KR20110018898A (en) | 2011-02-24 |
KR101595042B1 (en) | 2016-02-17 |
RU2486234C2 (en) | 2013-06-27 |
US20160296570A1 (en) | 2016-10-13 |
EE201800005A (en) | 2018-07-16 |
EE05341B1 (en) | 2010-08-16 |
DK3193895T3 (en) | 2020-07-20 |
EP3193895A1 (en) | 2017-07-26 |
WO2009138092A1 (en) | 2009-11-19 |
EP2288360B1 (en) | 2011-12-14 |
ATE536879T1 (en) | 2011-12-15 |
PL2288360T3 (en) | 2012-06-29 |
US20110274789A1 (en) | 2011-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10272122B2 (en) | Lactobacillus plantarum inducia DSM 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against Clostridium difficile | |
de Souza et al. | Lactobacillus casei and Lactobacillus fermentum strains isolated from mozzarella cheese: probiotic potential, safety, acidifying kinetic parameters and viability under gastrointestinal tract conditions | |
Uriot et al. | Streptococcus thermophilus: from yogurt starter to a new promising probiotic candidate? | |
JP7168558B2 (en) | Treatment of Clostridium difficile infections | |
Ebel et al. | Impact of probiotics on risk factors for cardiovascular diseases. A review | |
Torres-Maravilla et al. | Identification of novel anti-inflammatory probiotic strains isolated from pulque | |
Dicks et al. | Probiotic lactic acid bacteria in the gastro-intestinal tract: health benefits, safety and mode of action | |
Sanchez et al. | Probiotic fermented milks: present and future | |
Sirilun et al. | Characterisation of non human origin probiotic Lactobacillus plantarum with cholesterol-lowering property | |
JP4706016B2 (en) | Bifidobacterium in the treatment of inflammatory diseases | |
KR101587195B1 (en) | Isolated microorganism strain lactobacillus plantarum tensia dsm 21380 as antimicrobial and antihypertensive probiotic, food product and composition comprising said microorganism and use of said microorganism for preparation of antihypertensive medicine and method for suppressing pathogens and non-starter lactobacilli in food product | |
Santos et al. | Safety, beneficial and technological properties of Enterococcus faecium isolated from Brazilian cheeses | |
Thakur et al. | Probiotics, Selection criteria, safety and role in health and | |
Jeronymo-Ceneviva et al. | Probiotic properties of lactic acid bacteria isolated from water-buffalo mozzarella cheese | |
CN112204129A (en) | Lactobacillus plantarum KBL396 strain and application thereof | |
Songisepp et al. | Safety of a probiotic cheese containing Lactobacillus plantarum Tensia according to a variety of health indices in different age groups | |
Önal Darilmaz et al. | The effects of inulin as a prebiotic supplement and the synbiotic interactions of probiotics to improve oxalate degrading activity | |
JP2017515799A (en) | Lactobacillus plantarum Inducia strain DSM 21379 as an antimicrobial agent against cholesterol lowering agents and Clostridium difficile | |
KR20170093586A (en) | Novel Lactobacillus plantarum with probiotic activities and use thereof | |
Zhijing et al. | Screening beneficial bacteriostatic lactic acid bacteria in the intestine and studies of bacteriostatic substances | |
US20140328814A1 (en) | Antimicrobial and antihypertensive probiotic composition, food product and dietary supplement comprising microorganism strain lactobacillus plantarum tensia dsm 21380 and method for suppressing contaminating microbes in a food product | |
EP2220210B1 (en) | Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect | |
Strompfová et al. | Lactobacilli and enterococci—potential probiotics for dogs | |
Chaudhari et al. | In vitro and in vivo evaluation of probiotic potential and safety assessment of Bacillus coagulans SKB LAB-19 (MCC 0554) in humans and animal healthcare | |
Sherwani | Probiotics in processed dairy products and their role in gut microbiota health |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TERVISLIKU PIIMA BIOTEHNOLOOGIATE ARENDUSKESKUS OU Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MIKELSAAR, MARIKA;SONGISEPP, EPP;HUETT, PIRJE;AND OTHERS;SIGNING DATES FROM 20140620 TO 20140630;REEL/FRAME:033219/0162 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: TERVISLIKU PIIMA BIOTEHNOLOOGIATE ARENDUSKESKUS OU Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 033219 FRAME 0162. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MIKELSAAR, MARIKA;SONGISEPP, EPP;HUETT, PIRJE;AND OTHERS;SIGNING DATES FROM 20140620 TO 20140630;REEL/FRAME:040365/0821 |